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vWHAT IS A WITNESS SEMINAR?
The Witness Seminar is a specialized form of oral history, where several 
individuals associated with a particular set of circumstances or events are invited 
to meet together to discuss, debate, and agree or disagree about their memories. 
The meeting is recorded, transcribed, and edited for publication. 
This format was first devised and used by the Wellcome Trust’s History of 
Twentieth Century Medicine Group in 1993 to address issues associated with 
the discovery of monoclonal antibodies. We developed this approach after 
holding a conventional seminar, given by a medical historian, on the discovery 
of interferon. Many members of the invited audience were scientists or others 
involved in that work, and the detailed and revealing discussion session 
afterwards alerted us to the importance of recording ‘communal’ eyewitness 
testimonies. We learned that the Institute for Contemporary British History 
held meetings to examine modern political, diplomatic, and economic history, 
which they called Witness Seminars, and this seemed a suitable title for us to 
use also. 
The unexpected success of our first Witness Seminar, as assessed by the 
willingness of the participants to attend, speak frankly, agree and disagree, and 
also by many requests for its transcript, encouraged us to develop the Witness 
Seminar model into a full programme, and since then more than 50 meetings 
have been held and published on a wide array of biomedical topics.1 These 
seminars have proved an ideal way to bring together clinicians, scientists, and 
others interested in contemporary medical history to share their memories. We 
are not seeking a consensus, but are providing the opportunity to hear an array 
of voices, many little known, of individuals who were ‘there at the time’ and 
thus able to question, ratify, or disagree with others’ accounts – a form of open 
peer-review. The material records of the meeting also create archival sources for 
present and future use.
The History of Twentieth Century Medicine Group became a part of the 
Wellcome Trust’s Centre for the History of Medicine at UCL in October 
2000 and remained so until September 2010. It has been part of the School 
of History, Queen Mary, University of London, since October 2010, as the 
History of Modern Biomedicine Research Group, which the Wellcome Trust 
1  See pages 109–114 for a full list of Witness Seminars held, details of the published volumes and other 
related publications.
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funds principally under a Strategic Award entitled ‘The Makers of Modern 
Biomedicine’. The Witness Seminar format continues to be a major part of that 
programme, although now the subjects are largely focused on areas of strategic 
importance to the Wellcome Trust, including the neurosciences, clinical 
genetics, and medical technology.2
Once an appropriate topic has been agreed, usually after discussion with 
a specialist adviser, suitable participants are identified and invited. As the 
organization of the Seminar progresses and the participants’ list is compiled, a 
flexible outline plan for the meeting is devised, with assistance from the meeting’s 
designated chairman/moderator. Each participant is sent an attendance list and 
a copy of this programme before the meeting. Seminars last for about four 
hours; occasionally full-day meetings have been held. After each meeting the 
raw transcript is sent to every participant, each of whom is asked to check his or 
her own contribution and to provide brief biographical details for an appendix. 
The editors incorporate participants’ minor corrections and turn the transcript 
into readable text, with footnotes, appendices, a glossary, and a bibliography. 
Extensive research and liaison with the participants is conducted to produce 
the final script, which is then sent to every contributor for approval and to 
assign copyright to the Wellcome Trust. Copies of the original, and edited, 
transcripts and additional correspondence generated by the editorial process are 
all deposited with the records of each meeting in the Wellcome Library, London 
(archival reference GC/253) and are available for study.
For all our volumes, we hope that, even if the precise details of the more 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable to all readers. Our aim is that the volumes 
inform those with a general interest in the history of modern medicine and 
medical science; provide historians with new insights, fresh material for study, 
and further themes for research; and emphasize to the participants that their 
own working lives are of proper and necessary concern to historians.
2  See our group’s website at www.histmodbiomed.org.
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INTRODUCTION
Psychiatric diagnosis is controversial and is regarded by some principally 
as a means of reinforcing the vested interests of medical professionals and 
pharmaceutical companies. On the other hand, the phenomena that are 
described in clinical psychiatric practice are real and clearly extend across time 
and between cultures. ‘In every culture there is some notion of emotional or 
psychological difference. Not all cultures identify these differences in the same 
way, nor do they use identical terms. Equally, however no culture is indifferent 
to those who are sad, frightened or unintelligible in their conduct.’1 
The description and diagnosis of Seasonal Affective Disorder (SAD) or ‘winter 
depression’ is a comparatively recent development which provides an unrivalled 
opportunity to explore the construction of a psychopathological entity through 
the relevant peer-reviewed publications, as well as the professional and public 
reaction to these scientific discoveries. This Witness Seminar provides a riveting 
insight into the thinking of some key protagonists, both the scientists who 
developed the diagnosis of SAD as well as those for whom this new clinical 
entity resonated so clearly with their own experiences. 
What is the point of diagnosis? Ideally a diagnosis should point to a particular 
disease process, though even in general medicine this is often not the case. 
However, in a pragmatic sense the value of diagnosis is that it enables a group of 
people manifesting particular clinical phenomena to be identified as sharing a 
common prognosis and response to treatment – in the case of SAD a therapeutic 
response to artificial bright light. Indeed with SAD, it may be that increasing 
knowledge about the circadian effects of bright light stimulated a search for 
medical conditions in which it might be effective, that is, in some sense the 
availability of a treatment led to the identification of the condition. 
How truly recent is the identification of SAD as a diagnostic entity? In fact, 
seasonal variation in mood disorder has long been recognized and Rosenthal 
and colleagues (1984) quote the eminent nineteenth-century psychiatrist, Emil 
Kraepelin, as commenting in his standard textbook: ‘Repeatedly I saw in these 
cases moodiness set in in autumn and pass over in spring … corresponding 
in a certain sense to the emotional changes which come over even healthy 
individuals at the changes of the season...’2 
1  Rogers and Pilgrim (2010), page 26.
2  Kraepelin, cited in Rosenthal et al. (1984), page 76.
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Kraepelin here is talking about bipolar disorder and raises some critical issues 
that are still relevant to the nosological status of SAD. Thus, is SAD really a form 
of bipolar disorder or does it make more sense to regard it as an exaggeration of 
a ‘normal’ seasonal mood change that might affect most of us to some degree? 
Original descriptions of SAD found that the majority of patients could be 
indeed diagnosed with bipolar disorder (winter depression, followed by mania 
or hypomania in the summer) but in subsequent samples, unipolar depression 
has predominated.3 Whether or not there are reliable seasonal changes in mood 
in the general population still seems uncertain, but if there are such changes, 
patients with mood disorders may be more sensitive to them.4
In current diagnostic frameworks such as DSM-V, SAD is regarded primarily as a 
mood disorder (recurrent major depression or bipolar disorder) with a characteristic 
seasonal manifestation, where the seasonal pattern is referred to as a ‘specifier’. 
However, Rosenthal (2009) has argued that SAD should be considered a separate 
diagnostic entity both from the point of view of a specific response to bright light 
treatment, a distinct ‘atypical’ depression symptom profile (over-eating, over-
sleeping, afternoon slump in energy), and a particular pathophysiology involving 
abnormal melatonin secretion and altered physiological responses to light.5 
Nevertheless, while bright light treatment is effective in the treatment of SAD, it 
is apparently also beneficial in non-seasonal depression and overall the number of 
patients studied in randomized trials is small; moreover, establishing a plausible 
placebo control has been problematic.6 Clinically, it does seem to be the case that 
SAD patients with the characteristic ‘atypical’ depressive symptom profile do best 
with bright light treatment,7 though atypical depressive symptoms are also seen in 
other depressive conditions, including bipolar disorder. Does bright light primarily 
treat the SAD disorder or rather, the atypical symptoms (which are not, of course, 
syndrome specific)? Finally, the nature of the pathophysiological abnormality in 
SAD is still not firmly established; Lewy’s hypothesis8 that SAD patients have 
abnormally delayed circadian rhythms that are corrected by morning bright light 
is compelling and elegant but not yet confirmed in a large sample of patients. 
3  Rosenthal et al. (1984); Thompson and Isaacs (1988).
4  Winthorst et al. (2014).
5  Rosenthal (2009).
6  Simon (2005).
7  Stinson and Thompson (1990).
8  Lewy et al. (2007).
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This Witness Seminar is particularly topical in view of the recent intense 
interest in the role of circadian rhythm and sleep physiology in a variety of 
mental health problems. This has been stimulated, in part, by fundamental 
research on ‘clock’ mechanisms in animals and the role of clock genes and their 
associated regulatory pathways in the circadian regulation of neural networks.9 
These advances promise greatly to enrich SAD research and should eventually 
help us decide whether SAD is much like other kinds of mood disorder or 
rather, is best considered as a distinct entity. 
This seminar is made particularly compelling by the testimony of some of 
the outstanding scientists and clinicians whose work led to the development 
of the concept of SAD. The studies of Josephine Arendt were fundamental in 
demonstrating the role of melatonin in the organization of seasonal and circadian 
rhythms, while Al Lewy’s groundbreaking discovery that melatonin secretion in 
humans could, in fact, be modulated by particularly bright artificial light laid 
the foundation for the modern light treatment of a range of circadian disorders. 
Norman Rosenthal used his own experience of the psychological effects of New 
York winters compared to those of his native South Africa to develop the clinical 
concept of winter depression and communicate this understanding to receptive 
patients and the public. Not then, a story of scientific progress through the 
crunching of ‘big data’ but more an account of how ingenuity, flair and a rather 
spontaneous coming together of the right people led to truly original discoveries 
and a new treatment for depression that has been appreciated by so many. 
Professor Philip Cowen
Professor of Psychopharmacology
University of Oxford
Figure A: Professor Philip Cowen
9  Foster and Kreitzman (2014).
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Professor Tilli Tansey: Thank you very much for coming here to the Wellcome 
Trust for our Witness Seminar on SAD. I’m Tilli Tansey and I’m the convenor 
of the History of Modern Biomedicine Group, which is based at Queen Mary 
University of London (QMUL).1 This format of Witness Seminars was devised 
in the mid-1990s as a way of recording and stimulating interest in the recent 
history of biomedicine and we invite a group of people, who have been involved 
in particular discoveries or changes or debates, to tell us what really happened. 
We want to get the stories behind the published, formal literature. We want 
to learn what stimulated particular fields or retarded discoveries, what were 
the unexpected successes and what were the failures and why? All of these 
conversations are recorded, transcribed, edited, and published. We produce 
hard copies and everything is also made freely available on our website. These 
are planned as informal meetings so we want everyone to contribute as and 
when you wish. Nothing will be published without your permission, and we 
will ask you to assign copyright to the Wellcome Trust. 
The subject of SAD came about as a result of a discussion between me and my 
colleague, Thomas Dixon, who is the director of the Centre for the History of 
Emotions at QMUL, and we thought it would be a very suitable far-ranging 
subject for discussion to have what we hope is the first of many collaborations. 
Thomas, do you wish to say a few words?
Dr Thomas Dixon: As Tilli just said I run the Centre for the History of the 
Emotions, the only such research centre, you might not be particularly surprised 
to hear, in the UK.2 One of our main areas of interest in the five years that we’ve 
existed is the relationship between the history of emotions and the history of 
medicine, emotions in health, and emotions in disease. When Tilli and I spoke, 
this seemed like a really excellent topic for investigating the recent history of 
emotions and health, as Seasonal Affective Disorder, or SAD, is one of those 
relatively rare conditions3 that’s come into common parlance – people who are 
not experts in the field make reference to it, describe, and experience their own 
emotional lives through this medical label of SAD. It’s something that’s got 
into popular culture. So for our purposes that makes it really interesting to look 
at the way that language has changed, experience has changed, and emotions 
change, all as part of the history of modern biomedicine. That’s probably 
1  See www.histmodbiomed.org
2  See the History of the Emotions website at www.qmul.ac.uk/emotions/index.html (visited 4 June 2014).
3  See later comments on page 31.
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enough to indicate why I think it’s really interesting, and how it fits with our 
work at the Centre. 
Tansey: The point of these meetings is not to hear from historians like Thomas 
and me but to hear from you, the authentic voices. What really went on? You’ve 
all been involved in different ways at different stages in the recent history of 
SAD. So to aid these discussions we’ve drawn up a brief outline programme 
(Table 1) and we hope that our discussions will broadly follow this format, but 
please feel free to contribute whenever and as often as you wish. 
What is SAD?
How, when, where, and why did it first appear? Relationship to views on ‘feeling 
low in winter’?
Who was/became involved (e.g. scientists, clinicians, patient groups, and funding 
agencies), when and how?
What is the evidence for SAD and has it changed over time? How widespread has 
SAD become? 
What have been the views of the psychiatric profession and other practitioners?
The theories of causation
What has been thought to be its physiological basis?
How and when did the concept arise of it being linked in some manner to our 
internal clocks (circadian or seasonal)?
What other physiological bases/explanations have been offered for SAD (unrelated 
to internal clocks but perhaps related to effects of season) 
Diagnosis and therapy
Diagnosis of SAD, how has it changed?
The development of specific therapies – failures and successes; commercial interests
Patient activism
How have therapies been thought to work?
What status have these therapies had in terms of clinical diagnosis, psychiatric 
practice, health insurance industry, etc? 
Table 1: Outline Programme for ‘The Recent History of Seasonal Affective Disorder (SAD)’ 
Witness Seminar
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An important component of all of these meetings, of course, is to find a suitable 
chairman. Sir Brian Follett is an endocrinologist who has spent much of his 
career studying biological cycles in animals and especially how many of these 
are controlled by changes in photoperiod. He has also served as Biological 
Secretary of the Royal Society, the chairman of the Arts and Humanities 
Research Council, and as Vice Chancellor of Warwick University. So he brings 
much relevant knowledge and experience to the role of today’s chairman, and 
Brian, we’re incredibly grateful to you for agreeing to take on this task and 
accept this invitation. 
Professor Sir Brian Follett: We’re here this afternoon not to produce the history 
of SAD but a history of SAD, so it won’t be a complete picture – indeed, 
there are ghosts in the room who are not here. I know rather little about the 
topic, and it is not an area I’ve ever worked on. But I have picked up a few 
thoughts: SAD was first recognized in the early 1980s4 but ever since there has 
been controversy as to whether SAD is a discrete condition and significantly 
more than a depressive state that happens to coincide with certain times of the 
year. The latest evidence is that SAD may be a real depressive condition that 
is seasonally triggered. It seems that we have to consider it to be a ‘complex 
4  Seasonal Affective Disorder was first described in 1984 (Rosenthal et al. (1984)). For a longer history, see 
Rosenthal (2006), pages 264–74; Wehr and Rosenthal (1989).
Figure 1: Professor Tilli Tansey and Professor Sir Brian Follett
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disorder with genes, environment and culture contributing to its etiology’,5 but 
that sentence worries me because that is the way so many ill-defined medical 
conditions are explained away. So what we’d like to do is to trace a history and 
establish what are the ‘facts’ and what is ‘opinion’. Let us begin and spend some 
time thinking about what is SAD? Then I’d like to turn to what its underlying 
physiological causation may be. That edges us into clocks and all sorts of things 
that are affected by day length. Finally, we will consider diagnosis and therapy. 
Professor Josephine Arendt: First of all I’m most honoured to be here. I’m not 
a psychiatrist but I have some very good psychiatrist friends and I’d like to say 
immediately that Norm (Norman Rosenthal) and Al (Alfred Lewy) advised me 
in 1984 on how to use light treatment for possible SAD in the Antarctic winter. 
I have photographs of this occasion.6 
The year 1984 really was the start of enormous interest in this whole area, 
which began, I think, because the time was right. We knew from the biologists 
and other scientists studying photoperiodism, for example our chairman, and 
5  Whitehead (2004). 
6  Professor Josephine Arendt wrote: ‘I had just been asked by the British Antarctic Survey to give the base 
doctor at Halley (75˚S) a research project to keep him busy. I have photographs of this occasion which 
happened during a Gordon Conference.’ Note on draft transcript, 29 January 2014. The photos were not 
of sufficient resolution to publish in this volume but copies are deposited with the records of this meeting 
in Archives and Manuscripts, Wellcome Library, London at GC/253. 
Figure 2: Professor Josephine Arendt
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Gerald Lincoln, my own group, and others, that day length governed seasonal 
responses in animals.7 We knew that the day length signal was pineal melatonin8 
and that its duration of secretion – long in short days and short in long days9 – 
told animal physiology how long the night (or day) was.10 We knew, thanks to 
Al, how much light it took to suppress melatonin completely11 and therefore in 
theory it was possible to devise a treatment of summer day length (i.e. shorten 
melatonin secretion with light) for a winter season of depression. Norm’s famous 
paper in 198412 and preceding case reports were the start of all of this.13 I will 
obviously not go into any more detail on that because particularly Norm and Al 
will have an enormous amount to say. 
There has been much discussion as to the mechanism and there are lots of 
theories around. My Antarctic interest proved to be a bit of a flop because we 
and others could find little SAD in Antarctica, just low mood and not in the 
winter, more in the spring.14 But giving a skeleton light treatment (a one hour 
bright light pulse in the morning and another hour in the early evening) without 
change in mood did produce a wonderful shift in circadian phase during the 
Antarctic winter.15 And I think that probably relates to some of the theories as 
to how light treatment works.
I won’t go into drugs at all but I’m sure lots of other people will. I’m really 
sorry that neither Chris Thompson nor Stuart Checkley16 are here because 
our other involvement was the ability to measure melatonin and its urinary 
7  Lincoln and Short (1980).
8  Herbert, Stacey and Thorpe (1978); Hoffmann (1979). 
9  Arendt (1979); Illnerová, Hoffmann and Vane˘cek (1984). 
10  Carter and Goldman (1983a and b); Yellon et al. (1985); Arendt (1986); Goldman (2001). 
11  Lewy et al. (1980). 
12  Rosenthal et al. (1984). 
13  Lewy et al. (1982); Rosenthal et al. (1983). 
14  Palinkas, Houseal and Rosenthal (1996); Harris et al. (2010). 
15  Professor Josephine Arendt added: ‘[This was] one of the first studies to show a light pulse phase shift in 
humans. See Broadway, Arendt and Folkard (1987).’ Note on draft transcript, 29 January 2014. 
16  Professor Chris Thompson is a practising psychiatrist and has been Chief Medical Officer of Priory Group 
since 2004; Professor Stuart Checkley is a retired consultant psychiatrist at the Maudsley Hospital, London 
and Emeritus Professor of Psychoneuroendocrinology. For further biographical details see the notes on pages 
80 and 86. Both Professor Thompson and Professor Checkley were invited to the Seminar but did not attend.
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metabolite 6-sulphatoxymelatonin17 both for NIMH (Norman Rosenthal and 
Tom Wehr) and for the Maudsley (Chris Thompson and Stuart Checkley).18 We 
helped them hopefully track what was happening in their SAD projects and I’m 
delighted to have been associated with these groups.19 Another person it would 
have been very nice to see would have been Tom Wehr (NIMH) but he doesn’t 
come to things very much these days I believe.20 
Follett: Thank you, Jo, for getting us started. Would you like to say something, 
Norman? 
Professor Norman Rosenthal: First I’d like to thank everybody for this lovely 
event and thank Jo for, as always, being so concise in encapsulating some of the 
key issues. I know that at this point you’re looking for what we in the United 
17  Arendt, Paunier and Sizonenko (1975); Arendt et al. (1985b). 
18  Thompson et al. (1988); Winton et al. (1989); Checkley et al. (1993); Murphy et al. (1993). 
19  Professor Josephine Arendt wrote: ‘We also collaborated with Anna Wirz-Justice at the University 
Psychiatric Clinic in Basel (for example, Wirz-Justice et al. (1996)) who has been very important in this 
field in Europe. She and Michael Terman (Columbia, NY) have been active raising the profile of light 
treatment and with Francesco Benedetti have recently published a clinician’s manual for the field (Wirz-
Justice, Benedetti and Terman (2009)).’ Note on draft transcript, 29 January 2014.
20  Dr Thomas Wehr is Scientist Emeritus at the National Institute of Mental Health and a psychiatrist in 
private practice in Bethesda, MD. See page 86 for further biographical information.
Figure 3: Professor Norman Rosenthal
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States call the backstory. So here are a few details from my own perspective. I 
came to the United States from South Africa in 1976 with my wife and little child 
and encountered experiences that I had never had before, namely when the days 
became short and dark I personally experienced a draining away of energy and 
a difficulty getting all my tasks accomplished for the three winters that I was in 
New York City. This turned around in the spring and I got my energy back, and 
each time I would think: ‘What the heck is going on here? What’s this all about?’ 
I never had had it before in South Africa, where Johannesburg is 26 degrees south, 
whereas New York is 40 degrees north. I didn’t put all the pieces together, but 
as the snow would melt I would think: ‘Oh, my energy’s coming back with the 
melting of the snow, what was that fuss all about these last three months? You 
can do everything, why were you exaggerating the difficulties?’ My wife had it 
much worse than me, she was virtually bed-ridden for some of that time. And 
so somewhere internally, something was getting encoded in me. Now at the time 
when I was studying psychiatry, the only thing I heard of was the ‘Christmas 
Crunch’. Patients would say to me: ‘Do you know, everybody in the office has the 
“Christmas Crunch” and they’re all having difficulties’ and that’s all that I heard 
about it. Winter depression was never taught in any way in my studies. I was 
going to do research at the NIH, I had the good fortune to be at a party where I 
met Al Lewy, who was dating a woman who was in our residency, and he talked 
to me about his melatonin study and I thought it was absolutely fascinating. He 
was working for a group that included Tom Wehr and was involved in rhythms 
of light and mood, not light so much then, the light was really the suppression 
of melatonin but was involved in circadian rhythms.21 So rhythms and mood 
and light were all kind of converging, and here I would like to agree with Jo 
that in a way the time was right, that there were a lot of converging lines. In due 
course I went to the NIH and joined that group, maybe Al was, in part, actually 
instrumental in helping get me into that group. Anyway, we started there and at 
that point an engineer named Herb Kern contacted us. He had kept diary records 
of his moods for many years and had hypothesized that they were seasonal and 
being driven by light. He came our way and wanted to be treated and Tom Wehr 
was very interested in sleep deprivation. I remember a pivotal discussion between 
Al and Tom and me, where Al said: ‘Let’s give him more light’, and Tom said: 
‘This is a perfect person to study sleep deprivation on.’ Tom was senior to Al 
and me, so he outranked us both and he could have ruled on it. I then chipped 
in and said: ‘Look, you can sleep deprive any depressed person but how often do 
you get somebody with this unique seasonal pattern? I think it would be a real 
21  See pages 12–15.
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waste and a shame not to try this highly novel treatment.’ And we did and he did 
actually come out of the depression and that’s all been written up in two separate 
case histories – one by Al, one by myself.22 Then it occurred to me that we needed 
more people with this problem. I solicited the opinions of local psychiatrists, none 
of whom had ever seen the problem, which really proves that if you don’t know 
what you’re looking for, you’re not going to see it. And they didn’t know what 
they were looking for but I figured, let’s go straight to the general public because 
people like me, had I seen an article in the newspaper, would have seen myself in 
that article. So a very lovely reporter from the Washington Post put in an article in 
which she described yet another patient who had this, who had been referred to us 
by a private psychiatrist named Dr Peter Mueller, who was also beginning to think 
there might be a group of people who are seasonally depressed.23 She was referred 
to us, she had a more typical pattern as it turns out than did Herb Kern, and we 
can elaborate later, but she was the sort of prototypical case vignette that we had, 
that this journalist put in her article. Thousands of people responded from all over 
the country. 24 That then became the basis for the syndrome or description and 
the basis for the first cohort of people to go into that first single blind study, the 
controlled study that was the subject of the 1984 paper to which Jo was referring.25 
Follett: Might I ask if this syndrome was widespread in Northern European 
society, but had not really been reported upon? Looking back, when was it 
detected in Scandinavia?
Rosenthal: Actually in Scandinavia it was recognized in the culture, because in 
the northern part of Sweden there’s a condition called lappsjuka, which means 
the sickness of the Lapps, which is essentially SAD. In the folk literature of 
Iceland they have a term called skamdegistunglindi, which means the depression 
of the short days. So it’s there in the cultural writings, if not in medical literature. 
In the medical literature a clear case first emerges by Esquirol in France of a 
businessman, who came to him at the beginning of the winter and said that in 
the last several winters he had had a depression that had come on very clearly. 
He was very concerned because it had influenced his judgement adversely and 
he was worried that he would do bad things, including violence to his family, 
22  Lewy et al. (1982); Rosenthal et al. (1983).
23  Dr Peter Sterling Mueller (1930–2013) was Clinical Professor of Psychiatry at the College of Medicine 
and Dentistry of New Jersey. See page 16.
24  For a more detailed account see Rosenthal (2013), pages 14–15.
25  Rosenthal et al. (1984).
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if he were not somehow treated. Esquirol took the seasonal pattern seriously 
and made the inference that the seasons were somehow driving these recurrent 
winter depressions and told him that he had to go down to the south of France 
and from there to Italy in anticipation of the winter, to pre-empt the subsequent 
depression.26 In fact the man did so and he successfully treated the depression. 
Subsequently, in the mid-1940s, there was a description of a patient called an 
‘unmarried clerk’ by a Colonel Frumkes. This man had this depression in the 
winter every year and Colonel Frumkes was heavily influenced by psychoanalysis 
so we have very complex descriptions and explanations for why apparently at 
the beginning of the winter he suddenly realised that masturbation was not a 
unique behaviour that he had only himself engaged in, but that in fact it was 
quite common practice, and apparently this at the beginning of the winter had 
plunged him into regular depressions. In addition, he was very disappointed in 
Mother Earth, who had let him down by all the trees losing their leaves and 
everything. So psychoanalytic explanations were offered to explain. So you’ve got 
this tremendous disjunction between the excellent clinical objective descriptions 
of the man’s depressions and what strike us today as very outrageous explanations 
for what is, after all, a rather simple, biological phenomenon.27 Incidentally, the 
history of SAD is documented in Winter Blues and Seasonal Affective Disorders & 
Phototherapy.28 And the history of SAD that I’ve reported to you, that’s in Winter 
Blues, was actually contemporaneously verified by all professionals concerned. I 
had each and every person who was involved in it, Al, Tom, Peter Mueller, Herb 
Kern, all basically sign off on it contemporaneously and say: ‘Yes, this is right’, 
because I didn’t want it to subsequently be regarded as my own subjective opinion. 
I modified and fixed it where anybody had any disagreements.
Follett: Al, is the ‘winter blues’ common in human societies and does it appear 
more strongly as one moves away from the equator and annual day lengths 
alter? In the history of SAD there appears to be a moment when it went from 
being, as it were, something one lived with, a few people suffered, to becoming 
a pathological condition that might be amenable to treatment. 
26  Jean-Etienne Esquirol (1772–1840) was a French psychiatrist who published his two-volume, Des 
Maladies Mentales in 1838. For a discussion see Rosenthal (2006), pages 268–9.
27  This case was published in the Psychoanalytic Quarterly in 1946 (Frumkes (1946)). 
28  Rosenthal (2006), pages 264–74; Rosenthal and Blehar (eds) (1989) pages 14–16. Professor Alfred 
Lewy added: ‘Regarding Norm’s account of the early history of SAD research, I would recommend a few 
other readings to fill in some of the details – Kern and Lewy (1990) and Battacharjee (2007).’ Note on draft 
transcript, 14 February 2014.
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Professor Alfred Lewy: First of all, thank you for inviting me to this great event. 
In my opinion, the key reason why we succeeded in ‘discovering’ SAD when it 
was more or less at least anecdotally reported to exist is that we simultaneously 
began to test a successful treatment, a treatment which was assumed to be related 
to its underlying mechanism; and, indeed, bright light remains the treatment of 
choice for SAD. Doctors don’t like feeling helpless and for them to feel really 
interested in a disorder they need to have a treatment. So SAD and light treatment 
came along almost at the same time: they came along in the case report of Herb 
Kern.29 There are many other parts of this story that we can get into, but I thought 
I might describe some of the early work I did at the NIMH with Tom Wehr and 
Fred Goodwin that led up to the time when Norm came to the NIMH and joined 
us when we went on to do the SAD work. I didn’t know anything about biological 
rhythms or melatonin or the pineal gland before I went to the NIMH in 1975 
and I joined the research group that Fred Goodwin headed.30 When I was the 
most junior person of this team, I went to Tom (this was in mid-1976) and I said: 
‘I’d like to make a contribution to the chronobiology work.’ It was circadian 
rhythm work at that point, not seasonal. ‘And I’d like to develop a technique for 
measuring melatonin in humans.’ So I went off into the lab for a couple of years, 
mentored by a brilliant organic chemist, Sanford Markey, who taught me gas 
29  Lewy et al. (1982).
30  Professor Frederick Goodwin (b. 1936) is Clinical Professor of Psychiatry at George Washington 
University. He joined the National Institute of Mental Health in 1965 where he was Director from 1992 to 
1994. See further biographical details on pages 82–3.
Figure 4: Professor Alfred Lewy 
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chromatography-mass spectrometry.31 We succeeded in measuring melatonin in a 
very accurate and precise way. To get a little bit personal about this, I remember 
the day in the lab, it was a weekend or an evening and there was nobody else 
around, and I realised then that the assay was going to work. You know you 
cannot publish a failed assay. You can barely publish negative results of a well-
done experiment; but a failed measurement technique, nobody is interested in it. 
But this assay got into Science in 1978.32 But before we sent our paper off, when I 
realised that the assay was going to work, I remember that moment when I was 
alone in the lab, calling my father up and telling him that I feel like I’m just 
putting the finishing touches on a rocket ship that can take me into outer space 
into unknown territory and it’s going to help me discover something – but I don’t 
know what it is yet. Now I have the tool to learn about melatonin in humans and 
how this may lead to something else. So my father said: ‘Well, let’s celebrate. Your 
godfather’ – my father’s best friend whom he met in World War II – ‘has just been 
named the Governor-General of Australia and I’d like to go visit him. Why don’t 
you come with me and we’ll see what the vice-regal life is all about?’ So we went 
to Australia for two weeks and when I returned to Washington DC I thought: 
‘Well, maybe we could measure my own melatonin in the morning and see how 
it decreases over successive days from night-time to daytime levels as my body 
clock readjusts to the East Coast Time Zone.’ I didn’t have a clue about non-
visual, ocularly-mediated light being able to affect humans; all the scientific papers 
suggested that humans were unique, and they did not suppress melatonin in 
response to light. Some very distinguished scientists were speculating that humans 
lacked the retinohypothalamic tract present in other non-human primates, such 
that they had the light suppression of melatonin capability but humans did not.33 
So I didn’t have an inkling about light suppression of melatonin at that point. I 
just wanted to test the daily rate at which my body clock adjusted through the 
time zones I crossed following my return from Sydney. I figured that just one 
(morning) sampling time point would initially show high melatonin levels, which 
would gradually decrease as my body clock adjusted to the DC time zone.34 To my 
31  Dr Sanford P Markey joined the NIMH in 1974 and is head of the Laboratory of Neurotoxicology of 
the Intramural Research Program. 
32  Lewy and Markey (1978). Professor Alfred Lewy added: ‘It remains the gold standard in the field, having 
directly validated (for example, Fraser et al. (1983)), and indirectly established the benchmark for all of the 
subsequent radioimmunoassays used to the present day.’ Note on draft transcript, 14 February 2014.
33  Perlow et al. (1980).
34  Lewy (1983b).
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surprise, the levels were low the first day and I thought: ‘Maybe sunlight is 
suppressing my melatonin levels?’ The difference between ordinary room light 
that previous investigators used and sunlight could be intensity, or it also could be 
the spectral differences, but in our simplistic way of thinking we just thought 
maybe it was intensity. So Tom Wehr and I first did a preliminary study of two 
individuals, who we had sleep between 3 in the morning and 11 in the morning 
for a week. Then we measured their melatonin profiles and then again on the 
eighth morning when we opened the windows and let the sunlight stream in at 
7am, we saw that the sunlight suppressed their melatonin. We never formally 
published this finding, which led us to do the following study with Fred Goodwin, 
David Newsome, and S P Markey.35 David was the ophthalmologist I asked to 
help because we were concerned about light toxicities.36 We were going to use very 
bright light in the eye, and most people then would not know what we now know 
is fairly safe if you use the right kind of light. Sandy Markey was my collaborator 
and mentor for the assay, and I wanted him to be a part of this research team as 
well. So we took six individuals and we used 2,500 lux, which is about five times 
brighter than ordinary room light, which is at its brightest around 500 lux; the 
2,500 lux light suppressed their melatonin production. We exposed these normal 
volunteers between 2 and 4 in the morning and then we took just two of them 
and gave them 1,500 lux and they had a halfway suppression. With just two 
people in one of the treatment groups, we went out on a limb and said: ‘There’s a 
dose-response curve here, or more appropriately, fluence-response curve: the 
brighter the light, the greater the suppression.’ And in that paper we said that 
bright light, including sunlight, might have effects on biological rhythms in 
humans as well. I would posit here, and people might want to comment one way 
or another, that that paper caused a paradigm shift in the field, having had 
numerous implications that we’re still trying to figure out the meaning of all of 
them.37 One of the implications was that if humans use electric light or indoor 
35  Lewy et al. (1980).
36  Dr David Newsome (1942–2011) was head of the Retinal and Ocular Connective Tissue Disease Section 
of the National Eye Institute at the National Institutes of Health.
37  Lewy et al. (1980). Professor Alfred Lewy wrote: ‘This study was the first demonstration of any light 
suppression of melatonin in humans.’ Note on draft transcript, 14 February 2014. Professor Josephine 
Arendt added: ‘There was however already some evidence for light control of circadian rhythms (Orth and 
Island (1969)).’ Note on draft transcript, 19 June 2014. Professor Alfred Lewy commented: ‘In response 
to Jo Arendt’s reminder about the above reference, which – along with related citations – were duly 
acknowledged in our original contribution (Lewy et al. (1980)), I am also reminded that with the passage 
of so many years now is a good time to try to arrive at an informed and objective consensus as to which 
findings were key (and why).’ Email to Ms Caroline Overy, 4 July 2014.
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light in the winter starting around 5pm to bedtime, it is not sufficiently bright to 
affect melatonin production or biological rhythms: we still may be responding to 
the short natural photoperiod (day length) because even on a cloudy, rainy day it’s 
at least 10,000 lux outdoors during almost all of the day. Thus, we could be 
experiencing a shorter day in the winter versus a longer day in the summer and 
therefore have a seasonal signal that wasn’t being perturbed by our use of usual 
intensity indoor light. Another implication was that we could have our circadian 
rhythms cued to light as well but again it would have to be natural daylight, 
usually in the morning, to reset our 24-hour rhythms every day, because, as we all 
know, most of us naturally drift a little later each day in the absence of any resetting 
cue. In other words, we need a morning light cue to reset us to precisely 24 hours. 
One reason why this paper caused a paradigm shift was that the received wisdom 
was that light did not suppress melatonin in humans and that light did not affect 
circadian rhythms in humans.38 The received wisdom then was that social cues 
were the main synchronizers of human circadian rhythms, that humans had 
evolved in such a way, that we were so intelligent, that we had risen above control 
by the light/dark cycle. All that thinking changed with our 1980 Science paper. 
There were some other implications of that paper as well.39 It was just after we 
discovered light suppression of melatonin production in humans and were in the 
process of writing this up when Herb Kern contacted us and told us about his 
38  Wever (1979).
39  Professor Alfred Lewy wrote: ‘The work done by previous researchers did not use sufficiently intense 
light, which is why they concluded that humans did not respond to non-visual ocularly-mediated light. To 
his credit, Lennart Wetterberg was perhaps the first to acknowledge that our demonstration that “strong” 
bright light could suppress melatonin in humans (Wetterberg (1980); Wetterberg (1981)). [This] was what 
led him to increase the light intensity in his subsequent studies, for example his first bright light treatment 
study (Beck-Friis et al. (1986)). I should also probably mention here that the first investigator to actually 
test our suggestion using bright light was Dan Kripke (Kripke (1981)), and, to his credit, Wever was the 
first to use our work to show successfully that bright light could reset biological rhythms in humans (Wever, 
Polasek and Wildgruber (1983)), although he did not hold the sleep-wake cycle constant. We were to 
do that (Lewy, Sack and Singer (1984); Lewy, Sack and Singer (1985)) which according to at least one 
investigator was important (Czeisler et al. (1986)). Another implication of our finding that melatonin 
production could be suppressed by light in humans was that melatonin should be sampled under dim light, 
so as not to suppress its production, in order to use endogenous melatonin as a marker for the timing of 
the body clock. And another implication was that some blind people might have free-running rhythms. Yet 
another implication was that artificial light could be used to experimentally, and perhaps therapeutically, 
manipulate circadian rhythms in humans, provided it was of sufficient intensity.’ Note on draft transcript, 
14 February 2014.
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seasonal mood cycle.40 He had read about the melatonin assay and he wanted me 
to measure his melatonin rhythm because he was a very bright and knowledgeable 
guy who had read all about the photoperiodic work and seasonal rhythms in 
animals and knew that length of day was important as well as the duration of 
night-time melatonin production in regulating seasonal rhythms, and he wanted 
me to measure his melatonin profile. I said: ‘Well, I’ve got a better idea, we can do 
that, but we’ve just discovered that light can suppress melatonin production in 
humans, so why don’t we try treating your next winter depression with light? 
Herb wasn’t the typical Seasonal Affective Disorder patient.41 He contacted us 
when he was hypomanic, of course. He had been to several psychiatrists up and 
down the east coast of the United States where many famous expert psychiatrists 
live and work. And, with the exception of Dr Peter Mueller, they were not 
impressed with his type of mood pattern;42 and Herb (and Dr Mueller) even had 
some ideas about light therapy, but not about ‘bright’ light therapy. So then Norm 
joins the group, and Norm and Tom Wehr were also co-authors of the case report. 
I made Herb the second author of that case report.43 In this case report, we exposed 
him to a skeleton photoperiod. Animals, and again I’m speaking here with very 
little authority compared to the experts here like Gerald Lincoln, tell the time of 
the year because of the time interval between when they first get light in the 
morning and when they last see it in the evening, and so if you want to change 
their seasonal rhythms you don’t need to give them light all day long, you just give 
them light a little earlier in the morning and a little later in the late afternoon/
evening to extend their photoperiod. I figured 13 hours is a good spring 
photoperiod, so we gave Herb the light between 6 and 9 in the morning, and 4 
and 7 in the afternoon. That would be kind of a skeleton photoperiod. It was 
2,000 lux light. The time interval between 6 in the morning and 7 in the evening 
is 13 hours. And so Norm and I both followed him over a ten-day treatment 
regimen, and Norm and the nurses gave him some behavioural tests. Herb started 
to respond after about the third or fourth day, and the response was complete after 
ten days. That became the first case report of a patient with recurring winter 
depression treated with bright light. The title of that paper wasn’t SAD, it was a 
40  Kern and Lewy (1990); Battacharjee (2007).
41  Professor Alfred Lewy clarified: ‘He had a circannual mood cycle that did not strictly place his depressions 
in the same months each year, and he also became hypomanic when he wasn’t depressed.’ Note on draft 
transcript, 14 February 2014. 
42  See page 10.
43  Lewy et al. (1982). 
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manic-depressive with a seasonal cycle. I was first and lead author of this case 
report. Norm was first and lead author of another case report describing Herb’s 
prior mood episodes, and the title described Herb as a bipolar patient.44 Norm’s 
coining of the name and acronym, Seasonal Affective Disorder (SAD), came 
later.45 Norm made another important contribution when he wanted to contact a 
reporter, as he mentioned, at the Washington Post, but Tom and myself, being of 
the old fashioned school (in those days doctors didn’t advertise or seek publicity), 
were not in favour of this. But Norm talked to Fred, Fred gave his approval, and 
Norm turned out to be absolutely correct in getting the story into the Washington 
Post, because I think that was a fundamentally important step in recognizing that 
it was not just an odd quirk in one individual but that it was a major, important 
disorder that affected the broad community.46 
Follett: That deals really with the opening case. Let’s think a little about the 
context of when all this was happening. We are talking mid-1970s, by which time 
we understood a lot about photoperiodism and also circadian rhythms. Might 
I ask the biologists present, Gerald Lincoln and Rob Lucas, to wind back to the 
mid-1970s when, finally, we accepted that humans were just other mammals? 
Professor Gerald Lincoln: Yes, Brian and I were around in the 1970s talking 
about melatonin, duration of melatonin signalling and photoperiod time 
measurement responses in animal models. It was already evident that in 
photoperiodic organisms an endogenous clock-like mechanism controls seasonal 
biology. This was where I had a specific interest in SAD rhythmicity in man. In 
the animal world when you maintain organisms on constant light regimes they 
continue to express their seasonal rhythms due to the endogenous circannual 
clockwork. I remember correspondence with Anna Wirz-Justice, now working 
at the University of Basel, regarding a patient she had followed for 13 years with 
an unusual SAD syndrome.47 The subject expressed a nice profile for a variety of 
different phenotypic features of SAD that were repeated each year. The intriguing 
feature was that this syndrome ‘free ran’ with a period of approximately a year 
and the person appeared to be in such a chronic mental state to be oblivious to 
44  Rosenthal et al. (1983).
45  Rosenthal et al. (1984). 
46  See page 10. 
47  See Wirz-Justice, Kräuchi and Graw (2001). Anna Wirz-Justice is Professor Emeritus at the Centre for 
Chronobiology, at the Psychiatric University Clinic of the University of Basel. In 1981, she and Thomas 
Wehr were awarded the Anna-Monika-Prize for their work in the chronobiology of depressive illness. 
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the natural seasonal timing cues that might normally operate. We were familiar 
with the occurrence of free-running rhythms for the daily circadian system, so it 
always rang true to me to think of the SAD syndrome as a fundamental feature 
of seasonal biology. Man is no different from all the other animals in expressing 
aspects of seasonality. And when Ebo Gwinner published his book in 198648 
we already knew that circannual rhythmicity was found in many organisms 
across different phyla – in plants, in insects, and even in single-celled organisms. 
Endogenous circannual timing is ancient and ancestral, so why not expect to 
find it in humans? I’ve listened to people talk about SAD and I always think 
that ‘SAD’ is a misnomer because it implies a negative feature of man’s biology 
while it evolved, in my eyes, as an adaptation to cope with the winter as an 
anticipatory timing process. Shut down for winter and then re-activate in spring 
using changes in daylight as the cue.49 
Professor Rob Lucas: I wasn’t really around in the 1970s. I’m sorry if that’s 
tactless but I guess the other sort of science that it maybe would have fitted 
in with was functional neuroanatomy. The appreciation that photoreception 
might be relevant for other things than just vision. Part of this was the discovery 
of projections from the retina to bits of the brain other than conventional visual 
48  Gwinner (1986).
49  Professor Gerald Lincoln added: ‘In our 24/7 world it might seem to be maladaptive.’ Note on draft 
transcript, 4 February 2014. 
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centres, in particular Bob Moore’s work identifying retinal projections to the 
suprachiasmatic nucleus (SCN).50 So that’s a really important idea I guess that 
it would have fitted in with, this idea that it makes sense to have something 
that has a different kind of sensory capacity than what we’re used to for vision, 
because there’s more to what the retina does than just helping us to see. 
Follett: Well, let me say I think this is very much at the heart of SAD. If one 
looks at how mammals survive winter and desperately short days then it involves 
very profound changes. This began with observing how the fur changed and the 
timing of reproduction and it is really only in the last 20 years that we have 
realised the degree to which there are seasonal changes in metabolism. I lecture 
undergraduates on this and show a group of musk ox standing in northern 
Norway surrounded by snow and simply not moving for weeks on end: they 
were not hibernating but just standing there. In today’s context, what was their 
mind state? Perhaps to understand SAD we need to measure ‘mood’ in large 
mammals in winter because it can then be studied experimentally. 
Rosenthal: If I may, sir, with respect before we move on, just comment on 
a few things that people have said. The first is Herb Kern. I understand he’s 
recently deceased.51 He was a remarkable man. Al talks about his Science paper 
50  See, for example, Moore (1973).
51  Herbert E Kern died in September 2013, aged 96.
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being a paradigm shift and it certainly was. It really taught us that light can do 
more than just enable us to see – it was indeed a paradigm shift. But I would 
venture to say that there were several paradigm shifts. Before the meeting, Jo 
Arendt and I were talking and Jo was saying the idea had been among many 
people that in humans the pineal was a vestigial organ and that melatonin was 
not consequential, which turns out not to be true at all. So Jo’s actually pursued 
the measurement of melatonin, to study its role in humans (and other species), 
even when people were saying there could be no radioimmunoassay for such 
small molecules, and very high level people saying that you couldn’t have a 
radioimmunoassay. Jo just barrelled on and figured out that it could be done.52 
So there were many people who challenged conventional orthodoxies. When he 
wasn’t depressed, Herb Kern had an irrepressible spirit and an energy. He was 
a short man with a crew cut and, although 63 at the time, was very energetic 
and very enthusiastic about our work – a total collaborator in every sense. I just 
wanted to pay a word of respect to a wonderful human being who also had a 
paradigm shift, in that he flouted convention, which was that Mother Earth 
was disappointing you and simply because he didn’t have a psychological or 
psychiatric background, he saw it in physical terms as potentially driven by day 
length. So that’s one thing. The second thing is where did basic scientists in the 
field fall? It’s true that the emphasis had been on circannual rhythms. Like Anna 
Wirz-Justice’s patient, Herb was one of those patients who was not typical of 
the usual SAD patient, but actually illustrates circannual rhythms as you can 
see in the diagram, the double plot in my description of his circannual cycles.53 
So some do have circannual cycles but many do not. There was, however, a lot 
of scepticism about whether there was any relevance in the animal world to 
SAD and I know that Nicholas Mrosovsky, whose book Hibernation and the 
Hypothalamus had fascinated me,54 wrote ‘Chipmunks in the Sky’ in a book I 
edited in collaboration with Mary Blehar, and said this about SAD: Let’s say 
you had three moles [on your body] that happened to be in a straight line, we 
could call that mole alignment disorder or MAD, and similarly if you get three 
winter depressions it could just be a coincidence.55 However, when I spoke with 
52  See note 17.
53  See Rosenthal et al. (1983), in which Herb Kern’s mood state data from his notebooks are double plotted 
on graphs to show the circannual rhythm of hypomania in the spring and depression in the autumn and 
winter.
54  Mrosovsky (1971). 
55  Mrosovsky (1989), page 140.
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him off the record he said: ‘You know those hibernating animals of mine, if you 
stress them and challenge them they look almost depressed. They do not want 
to be tinkered with in their hibernating state’ and I think that was very apt. I 
feel that it’s too bad that there’s been a lack of cross-fertilization because there 
are models for depression in animals and they could be used on hibernating 
hamsters and have, in fact, in some cases but it hasn’t really caught on. I know 
you said, Professor Tansey, at the beginning of this Witness Seminar, that this is 
not only to recapitulate history but also to stimulate future interest, and I think 
there is an incredible opportunity for interaction between basic and clinical 
scientists on this particular area. 
Arendt: I’d just like to make a couple of comments, one of which is slightly 
off the wall because I mentioned earlier this obscure region, Antarctica, where 
I have done quite a lot of research.56 People have low mood not so much in the 
autumn but more in the spring, and I wondered if that was evidence if you like 
of a retained circannual rhythm, which is appearing at the wrong time of year 
because they are ‘out of phase’ having travelled to the southern hemisphere. 
Secondly, I would just like to underline the contribution of Herb Kern. I was 
lucky enough to meet him, what a fantastic thing to do, to go and self-diagnose. 
Related to this field I have another example of self-diagnosis because we know 
that melatonin is going to come up in this SAD discussion in terms of melatonin 
treatment as a chronobiotic. We first described its phase-shifting effects in the 
56  See page 7.
Figure 7: Professor Norman Rosenthal and Professor Josephine Arendt
The Recent History of Seasonal Affective Disorder (SAD)
22
early 1980s57 and I was rung up by a chap called Harry Kennet in 1986: ‘I’m 
completely blind,’ he said, ‘and I have non-24-hour sleep-wake disorder’ – not 
in exactly those words as it had not been defined at that time. ‘Can I have some 
melatonin?’ he asked. And so we gave him a placebo controlled cross-over study. 
Melatonin stabilized his sleep-wake cycle for the rest of his long life.58 From 
this and subsequent studies from our group and Al Lewy’s group, we know 
that melatonin can synchronize circadian rhythms in humans.59 These two self-
diagnosed people have shifted the field substantially more in some respects than 
we scientists, it seems to me.60 
Tansey: May I just ask a question, and that’s the influence of your case study. 
When you wrote about Herb and you wrote your first paper actually naming 
SAD, what kind of influence did it have? Do you have any citation numbers? 
How were your professional colleagues reacting?
Rosenthal: Yes, when you look at the citations of that 1984 paper, they continue 
to climb, but less markedly than in the earlier years of SAD. There are about 
1,200 citations of that paper more or less so far, and after 10 years the people 
who put out Citation Reports had me do it as a Citation Classic.61 That was after 
ten years indicating that it was cited much more than other papers in the field. 
So that is some evidence. I would say that it has been much more embraced 
by the general public who identify with the symptoms than by the medical 
profession. I think that’s a serious problem because Al said, and correctly so, that 
doctors will only recognize a disorder when they have a treatment. And I think 
that’s partially true. I’ll say it slightly differently: if they don’t have a treatment 
they’ll never recognize the disorder, or very rarely. But here’s a case where they 
do have a treatment and they still don’t recognize the disorder and I know 
that I’m sitting in the hallowed halls of the Wellcome Trust whose progenitor 
57  Arendt et al. (1984); Arendt et al. (1985a); Wright et al. (1986).
58  Arendt, Aldhous and Wright (1988); Arendt (1997). Professor Josephine Arendt wrote: ‘He died in 2009 
of prostate cancer, and he also co-authored one of our papers.’ Note on draft transcript, 29 January 2014. 
59  Lockley et al. (2000); Sack et al. (2000); Lewy et al. (2005).
60  Professor Josephine Arendt added: ‘Incidentally I am aware that Stuart Checkley successfully treated a 
registered blind lady for SAD with light – but she may have had some residual light perception or indeed 
retained hypothalamic light perception.’ Note on draft transcript, 29 January 2014.
61  Citation Classics, comprising a one-page abstract and commentary, were written by authors of highly 
cited papers as identified by the ISI Citation Indexes. This article was cited over 380 times; see Rosenthal 
(1993).
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was Burroughs Wellcome and whose source of revenue was the pharmaceutical 
industry.62 However, the pharmaceutical industry remains a dominant force, 
maybe not here, but at least in the United States, in publicizing, promoting, and 
educating people, and insofar as light is not a drug and not patentable, there has 
not been this kind of flow of information by major highly funded organizations 
– yet fortunately I’m here in the winter with Seasonal Affective Disorder but 
full of good spirits and energy because I have been sitting in front of my lights 
every single morning. I still can’t believe after decades of light therapy that 
medicine can come in through the eyes instead of through the mouth. It’s still 
almost unbelievable and I know we have Jennifer Eastwood over here who is the 
indomitable force who initiated the SAD Association of the United Kingdom 
which has been the most potent self-support group for SAD and she can testify 
to that potency. But why isn’t every person with SAD eligible for a light box by 
the National Health Service? It’s a one-time cost and look at what it would save 
in terms of misery and disability and time off work and so on and so forth. I 
don’t know how I got off onto that riff but I’ll get off my soap box and pass on 
the microphone, I’m not at Speakers’ Corner here.
Follett: If you stand off your light box [laughter] let’s turn to it because I’m still 
back here in the early days when it was a rare disorder and it’s being driven by 
individuals. Are they examples of a general phenomenon? One bit of evidence 
suggests it might be since, if you advertise, people sign up, but how did this 
develop here in the United Kingdom and in Northern Europe? 
Ms Jennifer Eastwood: I can tell you about the development of SAD in the 
UK as I was one of the first patients to be tested and diagnosed here in the 
1980s. Several years before we had heard of SAD in the UK, my first symptoms 
appeared at the age of 28 and I was diagnosed, to cut a long story short, with 
manic depression or Bipolar II. I wasn’t convinced that I was a manic depressive 
because I went to some Manic Depression Fellowship meetings and knew 
instinctively that I was different from the rest of them.
62  Sir Henry Wellcome (1853–1936) created the Wellcome Trust in his will dated 29 February 1932. It 
endowed two research charities, one to support the history of medicine and the other to support research in 
medical sciences. The Trust owned the umbrella organization, the Wellcome Foundation, which had been 
formed in 1924 by Sir Henrry Wellcome to include his libraries, museums, research laboratories, and the 
pharmaceutical company of Burroughs Wellcome & Co. until it was partially floated on the stock market 
in 1986, eventually merging with Glaxo in 1995, and becoming part of GlaxoSmithKline in 2001. For a 
history of the pharmaceutical company, Burroughs Wellcome, see Church and Tansey (2007). 
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During the next few years, psychiatrists Dr Stuart Checkley and Dr Chris 
Thompson (subsequently Professors) started SAD research clinics at the 
Maudsley and Charing Cross Hospitals, respectively. UK medics had the 
same constraints as those in the USA about advertising for patients, but Dr 
Thompson managed to bring the attention of the media to his SAD research so 
his early patients, including me, were able to apply directly to him to be tested, 
diagnosed, and treated for SAD, probably for the first time in the UK. 
Subsequently, through the SAD Association (SADA),63 I met people older than 
me who had spent winters in a psychiatric institution and seem to have had a 
much better time than most of us who were trying to live so-called normal lives 
in society. SAD was certainly around but nobody in the medical profession had 
appeared to recognize the seasonal connection. Anyhow, I hadn’t recognized 
my own seasonality except that, ironically, I hated the summer heat and much 
preferred the winter until I began to be ill. 
In 1985 I went along to Charing Cross Hospital where, in order to be tested 
and diagnosed, I had to go off all medication. I was on eight different drugs, 
including lithium, and, as I gradually withdrew them, I became very ill and was 
admitted to hospital, whereupon a very large, cumbersome light box, made in 
63  The Seasonal Affective Disorder Association (SADA), founded in 1987 by Ms Jennifer Eastwood, is a 
charity run by volunteers to support and advise people with SAD: www.sada.org.uk/index.html (visited 
12 March 2014).
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the hospital lab, was dragged to my bedside. I started to look at it and within 
three to four days, felt very peculiar and didn’t know what was happening. 
Somebody said to me: ‘You’re getting better’, and it was quite extraordinary 
because I’d relied so heavily on drugs, tried psychotherapy, taken extra holidays 
because they always said I was overworking – I’d tried everything. But this 
strange box full of bright white light tubes, supposed to replicate summer 
daylight, was the treatment that really hit the spot.
Similar research was being undertaken at the Maudsley Hospital, where they 
used light rooms instead of boxes to treat patients. By the time we started the 
SAD Association in 1987 to raise awareness of SAD, patients were applying to 
be seen at either Dr Checkley’s or Dr Thompson’s clinic. Almost immediately, 
SAD and SADA attracted a great deal of media attention and we were contacted 
by hundreds of thousands of people, most of whom were desperate for help.64 
I formed the somewhat cynical impression that, of those people who had been 
referred to a psychiatrist in the past, those that talked a lot were diagnosed 
as Bipolar II, and those who lay in bed and didn’t talk during the winter 
received a diagnosis of schizophrenia. It was as if, by and large, the professionals 
decided that your diagnosis had to belong either with the depressive illnesses 
or schizophrenia-type conditions, as if there were only two areas of functional 
psychiatric disorders. 
We at SADA soon realised that in many cases, SAD was a very serious illness 
and it was important that patients should be diagnosed and treated before their 
lives were completely destroyed and they committed suicide. Some didn’t make 
it and we were aware of a number of suicides.65 
It’s usually seen as the winter blues that many people experience but it isn’t for 
a number of us. I’ve often wondered how an animal feels with their version 
of SAD but one thing I know is that when an animal goes into hibernation, 
everything stops. They don’t have to function in society during the winter and 
it’s that that causes the problem.
64  Ms Jennifer Eastwood wrote: ‘It was probably the first time that Seasonal Affective Disorder was 
described and recognized in the UK though many of our correspondents were aware of it and had self-
diagnosed.’ Note on draft transcript, 31 January 2014.
65  Ms Jennifer Eastwood added: ‘I remember the first time a coroner ruled that a suicide was due to SAD; 
it caused a stir as few professional or lay people were aware of the severity of SAD.’ Note on draft transcript, 
31 January 2014.
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Follett: Jo, how did it strike you in the early days as it was becoming clear that 
SAD was more widespread here in Europe than we had thought?
Arendt: Well at that time I was collaborating with a chap called Lennart 
Wetterberg, I don’t know if you’ve come across him? He’s a Swedish psychiatrist; 
he was very, very concerned about SAD right back in the late 1970s I would say.66 
In Sweden, after the NIMH revelations, it was taken up very rapidly. I have seen 
that Lennart had a very interesting way of going about it. He didn’t just treat 
people with light, he put them in an all-white room wearing all white clothes. 
I’ve no idea if there was a proper study done as to whether it was necessary to go 
that far but it was certainly taken very seriously in Sweden at that time. I should 
also say that Anna Wirz-Justice would tell you that Germany and Switzerland 
also took it very seriously.67 
Rosenthal: Thanks Jo. I just want to add that it was taken very seriously. I sat in 
one of Lennart’s wonderful bright rooms; it was a wonderful entity. I don’t know 
if Lennart’s actively working any more but in Sweden they have now declared 
that light therapy is not necessary or useful. There was an official document 
promulgated by whatever the powers that be are, because as soon as you say ‘light 
therapy is legitimate and necessary’ you are then committing yourself to a line item 
in the budget that’s going to cost a lot of money if everybody, which is probably 
the entire population of Sweden, wants a light box. So they do not accept light 
boxes as a legitimate treatment for SAD. I looked into what it would take to try 
to have experts elsewhere in the world try to contest that but apparently they 
don’t really take kindly to complete strangers giving their unsolicited opinions on 
matters. Jennifer, you can tell me whether the NHS will give people light boxes? 
Eastwood: No.
Rosenthal: So that’s a similar situation here. With that kind of situation, if you 
don’t have the option to give people these resources, you can see why doctors 
would not be incentivized to diagnose the condition and recommend it as a 
treatment.
66  Lennart Wetterberg (b. 1931) is Professor Emeritus of Psychiatry at the Karolinska Institute, Stockholm 
and was Director and Head of the Department of Psychiatry at the Karolinska Institute, St Goran’s Hospital. 
See the comment by Professor Alfred Lewy in note 39.
67  Professor Josephine Arendt wrote: ‘In Switzerland at least this was largely due to her efforts. She worked 
at NIMH with Tom Wehr, Al and Norm in the 1980s during those exciting times. Returning to Europe 
her enthusiasm for light treatment convinced many colleagues of its utility. In fact her advocacy continues 
undimmed today.’ Note on draft transcript, 29 January 2014.
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Follett: Let me go to Carol, who is from a company that manufactures light 
boxes.
Ms Carol Barksfield: Norm, I’ve been trying to get them on prescription this 
last year, and all I’m getting back from the NHS is that the National Institute for 
Health and Care Excellence (NICE) guidelines say there isn’t enough research on 
them, and that the research is inconclusive. That’s what I’ve had back. They want 
complete clinical papers, they will not take just abstracts, they want the whole 
thing. It’s been an absolute nightmare. I’ve been working on it since last April.
Arendt: I think education is a problem in fact. In my various supervisory 
activities with regard to young doctors whom I’ve persuaded to do a project 
related to light, at least two have told me that it was not part of any medical 
education and if they brought it up they were told it was rubbish.
Rosenthal: If I may say, I think this really is a huge compliment to you all for 
having this symposium because it shows that there are people who are genuinely 
interested in something where there is vast scientific evidence. The number of 
clinical trials, controlled trials, using every manner of placebo is extensive.There 
was one scientist, Charmane Eastman, who was one of the last highly informed 
sceptics and found some – often very minor – flaw in every single study. She 
said every placebo was somehow defective in some way so she created her own 
placebo, which was a negative ion generator that had been deactivated, which 
was actually a brilliant placebo and she herself found the superiority of light, to 
Figure 9: Ms Carol Barksfield
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Figure 10: The Diamond Litebox and LitePod light boxes.68
her enormous credit because of her sceptical stance.69 So every knowledgeable 
scientific sceptic has pretty much been persuaded and I think it’s a sad indictment 
that science does not dictate policy.
Barksfield: They, NICE, just say that there isn’t enough clinical expertise in 
the field, which I feel, when you look around here, is quite absurd, but also the 
light boxes are very highly regulated. They have the Medical Directive 93/42 
come out of Brussels and we have to have all the light boxes tested to a very 
high standard.70 The light boxes are actually tested to the same standard as 
heart pacemakers and those sorts of invasive devices. It’s considered an invasive 
device because it changes the chemical balance in the brain. So we have to jump 
through all these hoops with the light boxes, but NICE cannot see them as a 
useful adjunct to treating any of these conditions.
Follett: It may all come down to politics. It’s no good railing against Lady 
Fortune and what one often has to do is alter the political world. Maybe what 
we need is an MP here this afternoon who understands about legislation. 
68  Ms Carol Barksfield wrote: ‘We have three different sizes of light boxes, Diamond, which is a large 
box with a quick treatment time and a large spread of light; the LitePod which we believe is the most 
popular light box on the market; and the newest one the LitePod LED, which is very compact and as yet 
has not been used in any clinical studies as we have not had it long enough.’ Email to Ms Caroline Overy, 
7 May 2014. 
69  Eastman et al. (1998). Charmane Eastman is Professor of Behavioral Sciences in the Biological Rhythms 
Research Laboratory at Rush University Medical Center, Chicago.
70  See Appendix 1 for the regulations with which light boxes need to comply.
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Can I go on and ask a question now? How many people are suffering from 
SAD? I assume that the range of suffering for many psychiatric diseases is very 
wide and at some point a clinician has to decide whether the person crosses 
a threshold or not, hence the arguments in The Diagnostic and Statistical 
Manual of Mental Disorders.71 Is there good epidemiological evidence as to how 
many people are suffering from SAD; what is the gender balance; what is the 
relationship between the number of people who are suffering in different cultures 
at different latitudes? This sort of evidence would be valuable in persuading 
people that we are dealing with a genuinely serious problem. Is there anybody 
who can contribute anything on this?
Arendt: Can I just say I think it’s fascinating that the Icelandic people have very 
few cases of SAD. And when they move to Canada likewise it’s really quite rare. 
Ms Helen Hanson: I think in Britain we’re quite famous for having four seasons 
in one day and I’m sure that this lack of consistency in the weather tends to 
make people see-saw. Certainly that’s the anecdotal evidence we’re getting at 
SADA. 
71  The Diagnostic and Statistical Manual of Mental Disorders (DSM) was first published in 1952 by the 
American Psychiatric Association. It is the standard classification for mental disorders. The most recent 
edition, DSM-V, was published in 2013. The third, revised third and fourth editions of the DSM are usually 
referred to as DSM-III; DSM-III-R and DSM-IV; the latest fifth edition is DSM-5. For consistency we have 
used Roman numerals throughout. See further discussion on the DSM on pages 41–2 and 49.
Figure 11: Ms Helen Hanson
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Rosenthal: Our group has done many, many studies on epidemiology of this 
condition and I think, as you so correctly pointed out, seasonality is a spectrum. 
The trouble is that it’s not only a spectrum in the population but it’s a spectrum 
in the individual. So you might have somebody who lives up in Canada who 
has got Seasonal Affective Disorder, who moves 500–600 miles down to North 
Carolina and has a mild case of winter blues, who then moves another several 
hundred miles south to Florida and then doesn’t have any problem at all. There 
are many individual cases of that kind where the latitude influences symptoms 
and so, in our original study, which Siegfried Kasper, who is now Chairman of 
Psychiatry at the University of Vienna, and I did, we developed a questionnaire 
that looked at seasonality and we developed case finding criteria, and found 
about 4.3 per cent of people in our part of the world, which is Maryland, 
Washington DC.
Follett: Which is about 40 degrees north? 
Rosenthal: 39 degrees. 4.3 per cent had a pure form of Seasonal Affective 
Disorder, as we defined it at the time, and about 13 per cent had the winter 
blues, which means they hadn’t sought medical attention but they recognized 
a fall-off in function and quality of life in the winter on a regular basis. Kasper 
and I wrote that up and that the winter blues responded to light as well. So we 
had 17 or 18 per cent, or one in five that reported some problem with winter.72 
Follett: Can I ask you whether the questionnaire placed major emphasis on the 
need for SAD to repeat annually, go away in the summer and reappear in the 
winter? 
Rosenthal: It doesn’t ask about seasonality in exactly that way, which would 
reflect the criteria for seasonal pattern, which had not yet been incorporated 
because it was still DSM-III in those days. So one in five showed some degree of 
problematic seasonal change at the latitude of Washington, DC. We later looked 
in Sarasota, Florida, New York, and up in New Hampshire, which is right at 
the Canadian border.73 And in Washington DC we personally interviewed 10 
per cent of the people to see to what extent our diagnoses corresponded to 
their questionnaire responses, and that’s how we determined our case finding 
criteria for SAD or the winter blues. That was the Seasonal Pattern Assessment 
72 Kasper et al. (1989). 
73  Rosen et al. (1990).
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Questionnaire (SPAQ).74 Now one of the problems in terms of determining 
prevalence of SAD is that depending on how strict your criteria are it’s going 
to be less or more prevalent. If I say you’ve got to have depression every single 
winter for the past five years, for example, you’re going to have virtually nobody 
who meets the criteria. For example, by now Jennifer has discovered that she 
needs to go to Malta in the winter, or wherever, to alter the course of her SAD.75
Eastwood: The Canary Islands.
Rosenthal: She goes to the Canary Islands in the winter, she doesn’t have a 
seasonal depression in the winter. So these people with SAD, they’re nobody’s 
fool. They know that they’ve got to get out of the winter one way or another. 
You know they’re not going to have one every winter because last winter they 
figured out a way to work in Miami, Florida or whatever. So the more stringent 
your criteria are, the more you narrow that spectrum, the less you’re going to 
find. I think it was Dr Dixon who started off by saying this is a rather rare 
condition,76 but I’ve spoken many times to an auditorium of say a hundred 
people and I’d say: ‘How many of you have difficulties in the winter that are 
significant? Difficulties concentrating and functioning’, and it’s rarely less than 
a quarter of the room that puts their hand up. So we’re not dealing with a 
very rare condition like Lou Gehrig’s disease or maple syrup urine disease, 
we’re dealing with something that’s more like diabetes just in terms of the gut 
response you get.77 I encourage people to check it out this week when you talk 
to others. Recently I talked in Seattle, which is very rainy, and the person who 
introduced me said: ‘How many of you people have heard of Seasonal Affective 
Disorder?’ The general response was ‘Oh yeah’; everybody put their hand up and 
there was a visceral knowledge that they were signalling. So it’s quite common. 
Now in terms of what Jo was saying about Iceland: Yes, the Icelanders seem to 
be protected. It may have been to their evolutionary advantage not to be too 
seasonal if they have to live in such a northern place. However, the Asian studies 
that we’ve done, we did them in Japan and China, also have very low rates of 
74  See Appendices 2 and 3 for the Seasonal Pattern Assessment Questionnaire (SPAQ), and the Daily Mood 
Log to record mood changes over the course of a day to help interpret the SPAQ.
75  Professor Norman Rosenthal added: ‘So, by people taking remedial action, they can no longer qualify as 
SAD if criteria are too strict.’ Note on draft transcript, 6 February 2014.
76  See page 3.
77  A rare disease, as defined by the European Union, is one that affects less than 5 in 10,000 of the 
population. For rare diseases in the UK see www.raredisease.org.uk (visited 9 April 2014).
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seasonality compared with elsewhere. But there is also widespread evidence of 
denial of SAD in places where it’s prevalent – as evidenced by the Swedes now 
retreating from saying that light therapy works, and the professionals here in the 
UK retreating as evidenced by the NICE criteria. The German-speaking world, 
on the other hand, has been really very supportive of seasonality and light 
therapy. Siegfried Kasper has led the charge there, and in Austria and Germany 
and Switzerland it’s easy to get light boxes and people know all about it and are 
interested in it. So there seems to be a cultural difference in that regard. 
Follett: Can somebody speak about cultures outside Northern Europe and 
North America? What is the situation in Japan and China? Do we also have 
information about Southern Europe? 
Eastwood: Over the years I have been contacted by any number of people from 
parts of the world like Egypt and India where you wouldn’t necessarily expect 
SAD to exist. I remember a Brazilian journalist coming to interview me so I 
looked at a map of the world’s latitudes and saw that Brazil goes quite a long 
way south. There are people with winter SAD in the southern hemisphere, 
Australia, New Zealand, and even the Falkland Islands.78 
I don’t know about Antarctica but I know that snow makes a huge difference 
to the intensity of light. I’m sure that is why so many people go skiing. I think 
maybe the worst area for SAD is the band around northern Europe where we 
have short day length, poor daylight in winter, and very little, if any, snow. We 
also have extremely polluted skies because of the highly urbanized, industrialized 
society we have in Northern Europe. I’ve been working in air pollution science 
at Imperial College London for 20 years and it’s taken me all that time to 
discover that the air pollution over London has caused there to be 12 per cent 
less radiant light than in the rest of the UK. 
I think we would all love to have some good epidemiological studies and 
therefore some accurate figures for SAD prevalence, even for one country but 
ideally more, because nobody really knows. About 20 years ago, Professor Chris 
Thompson and I came independently to the conclusion that there was 1–2 per 
cent prevalence in the UK of people with a psychiatric disorder so severe that 
they couldn’t function in winter. Winter blues were estimated to be about 20 
78  Ms Jennifer Eastwood added: ‘People from both northern and southern hemispheres have joined SADA 
over the years and have tried to set up SAD support organizations in other countries but they haven’t lasted.’ 
Note on draft transcript, 31 January 2014.
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per cent, and 90 per cent of the population was affected – not ill, just noticeably 
different in winter. I’m afraid I can’t remember offhand where those figures 
came from. 
Rosenthal: Professor Thompson has been quite critical of the Seasonal Pattern 
Assessment Questionnaire that has been the instrument that we’ve used. I think 
that the problem arises from the necessity for individuals to fit into the criteria 
created by the founders of the DSM-IV and -V; the criteria are much too rigid. 
I actually wrote to them but found them to be quite impervious to suggestions. 
I published my comments in the American Journal of Psychiatry and to their 
credit they gave me space to publish them.79 So they’re there for anybody who 
has any interest in the matter at all. I think often people, including scientists, 
respond to economic pressures primarily. So I feel that when you see the data 
in Sweden and the data in Britain that says people can’t have their light boxes, 
why don’t they just say: ‘We haven’t got enough money’? The light works and 
you should be entitled to it but we have a limited budget and we can’t afford 
it. That would be honest. Nobody says you’ve got to pay for anything if you 
haven’t got it in your budget to do so. But to suggest somehow that it doesn’t 
work is fundamentally incorrect in my view.
Follett: Okay, let’s think where we are. We have a disorder, which is being 
detected in a variable number of persons but nobody is sure about the actual 
incidence. If I were on NICE then I would ask questions about this lack of real 
numbers. Let us move to a second issue: What might be the physiological basis 
of SAD? 
Lewy: Well, certainly with the design of the skeleton photoperiod bright light 
treatment of Herb Kern we were thinking of a seasonal rhythms photoperiod 
and possibly suppression of melatonin to shorten its night-time duration. But 
when I left the NIH to be where I am today in Portland, Oregon, and by the 
way if you want a little personal note here, I signed the contract to come to 
Portland, Oregon, which is a mecca of winter depression as Norm knows, two 
months before we treated Herb Kern with light. It’s just very, very common 
in the Northwest, so that was a kind of lucky coincidence there. And I told 
the folks at Oregon: ‘I want to treat this patient with light, before I actually 
leave the NIH. I also want to look at some blind people, because we think 
if light is important to suppress melatonin maybe it’s a trigger for circadian 
rhythms.’ I showed with David Newsome, eventually published in 1983, that 
79  Rosenthal (2009). See also comments on pages 41–2 and 49.
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at least one blind person had a free-running circadian melatonin rhythm and at 
least one other blind person had an entrained melatonin that was abnormally 
phased (increased levels during the day).80 And there was one other study that 
I won’t go into now.81 When I got to Oregon I had a conversation with Norm 
on the phone and he told me that he had now been talking to several of these 
patients and he noticed that they had trouble waking up in the winter, that they 
had trouble getting up in the morning and were very slow to get started. So I 
thought about that and I thought about all the work that Tom Wehr had done 
on circadian misalignment between the sleep-wake cycle, which is cued to our 
alarm clocks and which is dictated by our spouse, our child, our pet, our boss, 
our anxiety level, and is therefore loosely coupled to the body clock, and the 
circadian rhythms are tightly coupled to the suprachiasmatic nucleus (SCN) in 
the hypothalamus, and that these two sets of rhythms could become misaligned. 
In this case, Tom Wehr was thinking of non-seasonal bipolar depression. He 
published a paper in Science in 1979 and his theory was that the circadian 
rhythms were advanced, were set early, with respect to the sleep-wake cycle.82 
However, I was thinking that in SAD, circadian rhythms may be delayed, or set 
late, with respect to the sleep-wake cycle, and that Norm’s finding of patients 
wanting to sleep late in the winter was an effort to try to self-treat by delaying 
their sleep to be in phase with their delayed circadian rhythms that were tightly 
coupled to the body clock that was shifting later in the winter with a short day 
but specifically with the later sunrise. 
Follett: Can we summarize the hypothesis? There is a 24-hour clock driving the 
timing of sleep. As day length alters seasonally then that precise position of sleep 
is shifting. In most cases we don’t even notice this change but it is occurring. 
Are you thinking that if one suffered from SAD then that positioning by the 
circadian system of the time of sleep was different from normal people?
80  Lewy and Newsome (1983). Professor Josephine Arendt wrote: ‘Note that others had also reported this 
phenomenon (Miles, Raynal and Wilson (1977); Orth et al. (1979)).’ Note on draft transcript, 19 June 
2014. Professor Alfred Lewy commented: ‘In response to Jo Arendt’s reminder about the above references, 
which – along with related citations – were duly acknowledged in our original contributions (Lewy and 
Newsome (1983); Sack, Lewy and Hoban (1987)), I am also reminded that with the passage of so many 
years now is a good time to try to arrive at an informed and objective consensus as to which findings were 
key (and why).’ Email to Ms Caroline Overy, 4 July 2014.
81  Professor Alfred Lewy wrote: ‘ … we showed that manic-depressives were supersensitive to light and that 
an expanded group of normal controls suppressed their melatonin levels by 50 per cent when exposed to 
500 lux light (Lewy et al. (1981)). Note on draft transcript, 14 February 2014.
82  Wehr et al. (1979).
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Lewy: Very well said. I would just like to add that there is a circadian rhythm 
in sleep propensity that’s tightly coupled to the SCN but we don’t always sleep 
at the time when our body clock would have us to sleep because of the other 
reasons I went into. So there’s this mismatch between the time we’re actually 
sleeping and are awake and when your body clock would have you be asleep and 
awake. And if that timing is delayed in the winter with the later sunrise, because 
once again it’s not getting outdoor light when we wake up in the morning 
that is the important time cue, your circadian rhythms will drift out of phase 
with sleep and in some individuals this will trigger depression. So that was 
the theory that I called the Phase Shift Hypothesis. I wanted to include Tom’s 
idea of a possible phase advance group, because perhaps they’re cueing to the 
earlier sunset in the winter. However, most patients with SAD are of the phase 
delay type, and therefore they need light in the morning, that would be the 
optimal time for these patients, as soon as they awaken, if possible, to reset their 
circadian rhythms earlier and push them earlier back into phase with the sleep-
wake cycle. That’s the theory.
Follett: So you give a pulse of light, which we know will alter the phase of an 
organism’s circadian system and you then tested in these patients whether or not 
a timed pulse of light could overcome SAD?
Lewy: Yes. So you mentioned earlier melatonin; is it a marker or does it do 
something more? And even though we give people melatonin for a number of 
reasons, as does Jo Arendt, we’ve used endogenous melatonin mainly as a marker. 
So we measured the melatonin rhythms in the SAD patients and specifically 
we measured one part of the profile, the melatonin onset. It switches on in the 
evening and it’s a very clearly demarcated event: when the SCN signals the pineal 
gland to make melatonin, levels shoot up like a rocket. This was shown by basic 
scientists in animals. It seemed to me that would be the best thing to focus on for 
the whole melatonin rhythm, representing the phase of the entire set of circadian 
rhythms that are tightly coupled to the SCN. I got a lot of resistance on this early 
on. I won’t mention their names but some very esteemed experts in the field said: 
‘Al, you’ve got to measure three days of data and average them to get the phase 
of a circadian rhythm.’ Maybe they were talking about temperature or cortisol 
which are noisy and you need at least 24 hours of data, and you can’t just use a 
little snippet of a window in the evening of say 6pm to bedtime, about a 5-hour 
window, but we did it. The other implication of the 1980 Science paper,83 the light 
suppression finding, was that you need dim light in the experimental conditions 
83  Lewy et al. (1980).
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when you’re using endogenous melatonin as a circadian phase marker; you don’t 
want to suppress its rise, you want to get its actual time and not a later time 
when you’ve switched the lights off. So we called this circadian phase marker 
the dim light melatonin onset, or DLMO,84 and it’s taken almost 30 years for 
it to be acknowledged as the best marker for body clock time in humans. We 
always thought this marker would be accepted by clinicians, especially measured 
in saliva, and by the way the earliest saliva work was done by Vakkuri,85 as we 
were doing it mainly in plasma. It’s convenient, and in saliva it’s non-invasive 
and you can do it at home. So you have this wonderful marker that’s important 
for a lot of reasons, such that I thought it would become a useful clinical tool. 
I never expected it to become the most accurate marker, and lo and behold, it 
is now considered to be not just the most convenient marker but as, or more, 
accurate than any other marker for the SCN in humans. So here in SAD we have 
not just a disorder but we have a marker for aspects of the disorder that we can 
measure in the home conveniently and hopefully this will become a standard and 
routine clinical test. If so, it will be perhaps the first clinical lab test in psychiatry 
(we can, of course, measure drug levels like lithium levels). But in psychiatry we 
have yet to find another biomarker that’s related to a psychiatric disorder that 
we can measure usefully. In sleep disorders medicine it may become the first lab 
test, after polygraphic recordings of sleep stages, to help us objectively diagnose 
advanced and delayed sleep phase syndrome.86 
Arendt: We, of course, use melatonin onset like lots of other people do. The 
one thing it doesn’t do, though, is tell you the duration of secretion. I think 
that’s a real pity. I’ve heard all sorts of people say that the reason for winter 
depression is long duration melatonin. And we still don’t know.
Follett: The technical point here is what factors are important in the melatonin 
rhythm: its onset, its offset, and/or its duration. All alter seasonally. And Al is 
saying that it turns out that the onset in the late evening is a very good indicator 
and in that sense a sensible indicator to measure if you’re trying to do it in 
populations of human beings, trying to do the duration. But I can immediately 
84  Lewy (1983a); Lewy and Sack (1989).
85  Vakkuri, Lappäluoto and Kauppila (1985).
86  Professor Alfred Lewy wrote: ‘Indeed, the DLMO can be used to phase type people (alone or with a sleep 
marker), it can be used to optimize treatment with bright light and low-dose melatonin because it marks the 
phase of their phase response curves (Lewy et al. (1992); Lewy et al. (1998a); Lewy (2007)), and (alone and 
with a sleep marker) it can monitor treatment with these phase-resetting agents.’ Note on draft transcript, 
14 February 2014.
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see the average scientist saying: ‘Well, it’s not the onset, it’s the duration.’ Dare 
I ask the question: among the people who presented with SAD what was the 
result relative to the normal population? Were they delayed or advanced?
Lewy: I agree that most scientists would probably first target the duration of 
melatonin production as important in SAD, given its importance in regulating 
seasonal rhythms in animals. However, we published in Science in 1987,87 again 
on a very small number of patients, eight patients that at baseline had a delayed 
melatonin onset compared to a group of seven normal controls and that when we 
gave them morning light we shifted their DLMO earlier. When we gave them 
evening light we shifted their DLMO later and when we gave them morning plus 
evening light – and now we’re using evening light at 8–10pm, so it’s later than with 
Herb Kern where I think it was falling on the dead zone of the phase response curve 
(PRC) – not to get into the weeds too much here, but we got an intermediate effect 
both in terms of the phase position of the DLMO and the antidepressant effect. The 
depression in seven out of the eight people in the group as a whole was significantly 
improved with the morning light. The mean depression rating with the evening 
light was no different from baseline and the combination of morning and evening 
light produced an antidepressant effect intermediate between that of morning light 
alone and evening light alone – again all very consistent supporting the idea that 
the mechanism is not duration of melatonin, it’s the circadian phase of the body 
clock and its relationship to the sleep-wake cycle (we held their sleep-wake cycles 
constant); most of them had a phase delay in their circadian misalignment and 
morning light is the best time to correct that phase delay by providing a corrective 
therapeutic phase advance.88 Then just to skip ahead here, but others may want to 
intervene a little bit, to 1998, Norm mentioned the work of Charmane Eastman, 
as well as Michael Terman, and our group published three papers back to back in 
the Archives of General Psychiatry where the shared conclusion was that morning 
was the best time to treat most patients with SAD.89 Since then I believe, others 
may differ here, that is the consensus.
Rosenthal: Yes, two points that Al raises that I really want to support and endorse. 
That is that the morning light has proven to be the most effective time aside from 
whatever mechanism might be involved. There’s consensus in the field and Al 
absolutely was the first to say so, and I want that to be on the record. I also want to 
87  Lewy et al. (1987a). 
88  Professor Alfred Lewy added: ‘This study also identified one individual who preferentially responded to 
evening light (Lewy et al. (1987a)).’ Note on draft transcript, 14 February 2014.
89  Eastman et al. (1998); Terman, Terman and Ross (1998); Lewy et al. (1998b). 
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address the segue by which the question of mechanisms was introduced: that is, how 
can we establish the prevalence of this condition if we don’t know the mechanism, 
as we do with HIV, for example? But in that case we would never be able to have 
the prevalence of any psychiatric disorder because there is no psychiatric disorder 
where there is a blood test or some other definitive acid test. Researchers thought, 
once upon a time, that the so-called dexamethasone suppression test was the litmus 
test for depression, but it turned out to be non-specific. The entire psychiatric 
canon hangs upon conditions that exist only in syndromal form, absent of any 
biological marker, so it doesn’t really seem fair to hold SAD to a higher standard. 
Another point, which has been introduced by Jo Arendt, relates to what we’ve 
heard throughout the day: that anything that happens in animals also happens in 
humans; that this notion that somehow, because we’re so smart, we’ve escaped our 
biological heritage, is not established and doesn’t hold up. In the animal kingdom 
there are essentially two oscillators, one that tracks dawn and one that tracks dusk, 
and depending on the duration of the day length these oscillators move apart in 
the summer and together in the winter. In fact, Tom Wehr in our group used 
methodology whereby he put people who had been sleeping or in the dark on a 
certain regimen, 14 hours in the dark, 10 hours in the light versus 8 hours in the 
dark and 16 hours in the light – a winter versus a summer photoperiod. They 
slept that way for weeks. Then he brought them in for a 24-hour period during 
which they were in very dim lighting conditions in which case the thumb print 
of the photoperiod of the previous couple of months would manifest itself in the 
melatonin duration. These were normal controls by the way. And what he found 
was that, as predicted, in the winter time the melatonin duration increased and in 
the summer time it decreased. In other words, melatonin profiles changed with 
photoperiod exactly as they do in sheep.90 However, what happened when he 
took these same individuals in winter and in summer when there was a natural 
photoperiod and scotoperiod corresponding to his experimental conditions, there 
was no difference between summer and winter melatonin profiles. So, what was 
essentially happening was that their ordinary daily use of artificial light, which was 
not regulated but was just as normal, was actually being perceived by these people – 
not visually but at some central location, be it the SCN, be it the pineal, whichever 
circuitry was involved – as though it was real summer time. They showed no 
difference in melatonin profiles between summer and winter under naturalistic 
conditions, but they did show a difference when they had to spend 16 hours in the 
dark. What that suggested was that the natural capacity of the human circadian 
90  For melatonin profiles in sheep, see, for example, Lincoln (2006); Lincoln and Hazlerigg (2010). See also 
note 97. 
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system to express photoperiod is preserved and intact, but normally overwritten by 
exposure to artificial light. Then he took patients with SAD, summer and winter 
in naturalistic lighting conditions, and what he found was that in the winter 
compared to the summer the duration of melatonin actually expanded under the 
24-hour constant conditions, without their having undergone any experimental 
manipulation ahead of time.91 So, in other words, the way we interpret those data 
is that somehow people with SAD have a higher threshold for perceiving light in 
whatever circuits and portions of the brain are relevant. They do not perceive the 
light as sharply, which would explain why they need extra bright light. The ordinary 
artificial light does not influence their duration of melatonin secretion and thereby 
influence their oscillators in a way that it does with healthy individuals. So Wehr 
and I have a somewhat different explanation from Al’s for the mechanism of what’s 
happening to the circadian system and how that’s causing the symptoms of SAD.
Follett: Not so much the duration of photoperiod but the intensity, the 
responsiveness to the intensity of light. We know that in circadian theory.
Lucas: I’m not sure if I’m allowed to ask a question but it interests me, the 
possibility that the idea of mechanisms here might reflect the time in history 
when SAD was described. That was a time when circadian and seasonal rhythms 
were of great biological interest and those concepts were starting to be more 
widely accepted. Where actually what we have is the correlation of light and 
the effect, and perhaps light might have influences other than on the circadian 
clock or melatonin rhythms that could explain this. Maybe that’s something 
that we understand more recently because of the appreciation that there are 
visual pathways influencing, quite fundamentally, aspects of physiology and 
behaviour that may not necessarily be by the clock. 
Lewy: Tom Wehr made a very important discovery in the sleep cycles of 
individuals under artificial very long nights and it should also be noted that they 
were in absolute darkness: no reading lamps, not a flicker of light.92 He made a 
brilliant discovery that the sleep bout changed into two bouts: an early bout and 
a late bout separated by a few hours of what he called quiet wakefulness. A lot has 
been written about this over the years as perhaps something that was biologically 
programmed when we evolved as a species, that this was a time that we needed 
for certain thinking or activities or something where we certainly didn’t get up, as 
there were a lot of predators out there at night that we didn’t want to encounter. So 
91  Wehr (1991, 1992).
92  Wehr et al. (1993).
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it stimulated a lot of very interesting anthropological and philosophical thinking 
along those lines. But I do not agree that there are two loosely coupled oscillators 
that control the melatonin production. Helena Illnerová from Prague has done a 
lot of brilliant work on this, but she’s been studying rats.93 It’s very interesting what 
we can and cannot translate from animals to humans, and what we can reverse 
translate from humans to animals. I’ll give you an example of the latter as a little 
bit of an aside here. After we showed that bright light could suppress melatonin in 
humans, Russel Reiter took some squirrels out of the wild and showed that they 
were insensitive to ordinary room light just like humans,94 as we had speculated in 
the last line of that Science 1980 paper.95 We’re adapting to bright light exposure 
all day long. We come indoors and are tested with laboratory light that is nothing 
in intensity compared to what we’ve been experiencing outside. It’s sort of a 
short-term adaptation. There are several papers out on this topic now, a variety 
of investigators looking at adaptation and short-term history of light exposure 
in humans. I’m sure Rob can comment on that as well. When Helena tried to 
test this amazing, clear-cut demonstration of two oscillators in rat – an evening 
oscillator regulating the rise of melatonin and a dawn oscillator regulating the 
fall of melatonin – it hasn’t been nearly as demonstrable in humans as it has been 
in rats.96 I would say that if there are two oscillators controlling the melatonin 
rhythm in humans then they are tightly coupled and do not change their phase 
relationship to each other very much during the usual experience of the natural 
and artificial light exposures across the year. In fact, in Tom’s paper I think they 
changed only by less than an hour in the natural photoperiod, which is much less 
than we see in sheep.97 And it was more in the males than in the females.98 And one 
of the things we skipped over earlier is that most patients with SAD are female.
93  See, for example, Illnerová and Vane˘cek (1982).
94  Reiter et al. (1982).
95  The last line of the paper reads: ‘Perhaps, by distinguishing among different light intensities, humans 
have adapted to artificial lighting while remaining sensitive to the natural light-dark cycle.’ (Lewy et al. 
(1980), page 69). 
96  Jelinkova-Vondrasova, Hajek and Illnerová (1999).
97  Professor Josephine Arendt wrote: ‘In 1979 and 1981 we reported extended duration of secretion in 
Suffolk Cross sheep living outside in winter with two peaks in some individual animals approximately 
nine hours apart and only one peak in summer. We have also observed two peaks in some human subjects 
without reference to season (Arendt (1979); Arendt, Symons and Laud (1981)).’ Note on draft transcript, 
29 January 2014.
98  Wehr et al. (2001).
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Eastwood: May I just reply to Al’s last comment? The female/male ratio 
published in research studies was usually 4:1.99 SADA used to do an annual 
questionnaire, which usually attracted 500+ responses, and the results were 
professionally analysed and sometimes published or presented at conferences. 
SADA’s female/male ratio was invariably 3:1, occasionally 2:1, simply because 
men in general do not like admitting to mental illness even if it’s from an 
external or environmental cue like SAD, and they are more reluctant to seek 
treatment or enlist in research studies. We used to find that, winter after winter, 
men would write to SADA, saying: ‘Help! Our wives are going to leave us/our 
secretaries have left us/I’m getting the sack’, and it was only because they were 
absolutely desperate that they were pushed into coming forward and saying that 
that they had something wrong with them.
There are many conditions where women are seen to be predominant but 
it is partly because women admit to symptoms and seek treatment. There 
are obviously more females with SAD because there’s a strong link with 
gynaecological/endocrinological disorders, e.g. postnatal depression is often a 
starter for SAD. It doesn’t matter how weird our circadian rhythms are, this 
illness is somehow triggered at a particular age in particular people, and its onset 
is at different times of life. For example, men sometimes become depressed 
when they give up work. They don’t realize that they’ve probably been depressed 
for years but they’ve taken it out on their families and colleagues. 
Follett: We must move off what you might call the circadian basis of some 
of SAD and move to diagnosis and therapy. SAD is starting to get traction 
as a genuine syndrome. There may be disagreements, or not, and these are 
reflected in the DSM-V manual. But in the most recent edition there is a clear 
set of statements about SAD. It is a recurrent major depressive disorder with 
a regular temporal relationship between the onset of major depressive episodes 
at a particular time of year. They do not lock it to winter but we’re focusing 
particularly this afternoon on winter ‘e.g. in the fall or winter’. And they want 
to exclude from this cases where there’s an obvious effect of seasonally related 
psychosocial stress, people who cannot gain employment in winter because 
their job is summer-related. And also they use the term ‘full remission’ or at 
least a change from major depression to mania or hypomania.100 Presumably 
these diagnostics arose obviously after the phenomenon had been discovered. 
99  See, for example, Leibenluft, Hardin and Rosenthal (1995); Lucht and Kasper (1999). 
100  See American Psychiatric Association (2013), pages 153–4.
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Rosenthal: I should start by saying that this is an unhelpful list of criteria and 
let us say that in the last two years my friend Jennifer – who has got one of the 
most classic documented cases of SAD on the records happened to go to the 
Canary Islands last winter and thereby escaped depression entirely but had had 
a depression every winter before that for the previous 19 years – would not meet 
the new criteria for SAD, because in the last two winters she would not have 
had two depressions. So that fact of needing it to have happened in the last two 
winters is entirely arbitrary without any basis in science and I could go on and 
on about problems with the DSM criteria. This issue of the seasonally variable 
occupational thing or seasonally variable precipitate has been in the canon of 
the DSM since DSM-III-R, the revised version of DSM-III. And that goes back 
probably to the late 1980s.101 I don’t know of anybody, myself included, who has 
ever seen a case where there is a reliable psychosocial variable that has explained 
the phenomena of SAD, so here’s a criterion that nobody’s ever seen but it’s 
stayed in the documentation. In any event this is not much different from what 
was initially entered in DSM-III-R. There was a twist, which was worse, when 
my colleague Bob Spitzer, who was a major nosologist,102 tried to quantify the 
necessary number of depressive episodes by saying there could be other depressions 
but there had to be at least a 3:1 ratio of seasonal to non-seasonal, that turned 
out to be almost impossible to implement. So the current definition has been 
how it has stayed. Incidentally, sometimes SAD patients take antidepressants 
before winter, which prevents the expected depression. My colleagues and I 
have actually done a study with Wellbutrin (bupropion) where we found that it 
prevented winter depression in a significant number of cases without any light 
therapy in a double-blind controlled study of a thousand subjects.103 We showed 
that it pre-empted the depression. Would that mean that that person in the study 
no longer suffered from SAD? According to these criteria, it would.
Follett: Thank you. You have advanced us onto the specific therapies and also 
introduced some pharmacology as distinct from light therapy, but how do the 
rest of you view these various therapies? We can now move the discussion, as 
Norman has done, onto what can we do for people who suffer from this? 
101  DSM-III was published in 1980 and the revised edition, DSM-III-R, in 1987.
102  Robert Spitzer was Professor of Psychiatry at Columbia University, New York and was chair of the 
committee for developing DSM-III.
103  Modell et al. (2005). Three randomized placebo-controlled prevention trials were carried out which 
resulted in a risk reduction of 44 per cent for patients taking Bupropion XL. For further comments on 
Wellbutrin see pages 44 and 48.
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Lewy: You can use melatonin as a therapy, and that’s a little counter-intuitive if 
you’re a believer in the photoperiodic hypothesis. We showed in the Proceedings 
of the National Academy of Sciences in 2006 that asymmetric lengthening of 
the melatonin duration in SAD patients improved their depression, because 
when we gave it in the afternoon they phase advanced.104 So low-dose melatonin 
(0.3mg was the maximum daily amount we used in that study) was given 
in the afternoon to extend the duration of the melatonin profile in order to 
produce a chemical dark signal to the body clock before signalling an earlier 
sunset. So we ‘advanced sunset’ with low-dose melatonin rather than advancing 
sunrise with bright light, and thereby caused a phase advance in the body clock 
relative to the sleep-wake cycle.105 So low-dose melatonin in the afternoon is 
an effective treatment for most patients (who are phase delayed). There is a 
smaller subgroup that positively responds to the melatonin administered in the 
morning.106 In either case, we’re lengthening the duration of melatonin, and this 
study convinced me that an increase in the duration of melatonin production is 
not causing people to get depressed in the winter and shortening it is not related 
to treatment with bright light. So, in fact, low-dose melatonin treatment can be 
used instead of light treatment. They’re both shifting the circadian clock, but 
you have to give them at opposite times of the day.
Follett: So the key thing is either light or melatonin as a means of shifting. 
Eastwood: Over 25 years SADA has studied and advised on the treatment of tens 
of thousands of people. Although we don’t have many scientific publications, we 
have had huge numbers of people, probably well over a million. I started SADA 
in 1987. After the first radio programme, which took place with Professor 
Thompson, we began to get thousands of enquiries from the public. There was 
a period of several years when, between November and February, I sometimes 
received a thousand or more letters a day, delivered in sacks from the post office. 
Nobody really believed me but I took a sack of letters to a meeting, emptied 
104  Lewy et al. (2006). 
105  Professor Alfred Lewy added: ‘In order to achieve overlap between the exogenous melatonin and the 
endogenous melatonin profile so as to optimize its phase-shifting effect (Lewy and Sack (1997)) the low dose 
was divided into even smaller equal parts, two hours apart, so that the first of these could be administered in 
the early afternoon and the last of these less than two hours before the endogenous melatonin onset.’ Note 
on draft transcript, 14 February 2014.
106  Professor Alfred Lewy wrote: ‘as large as one-third of SAD patients, larger than the 1/8th proportion who 
preferentially responded to evening light in the 1987 study (Lewy et al. (1987a)). Note on draft transcript, 
14 February 2014.
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them onto the floor, and showed my colleagues what was going on. Most of the 
writers claimed to have some degree of SAD and I know you can discount a 
large number of those as manageable, but nonetheless distressing, winter blues 
but some of the things I read were horrendous. When I see that there’s not a 
single UK psychiatrist in this room, it makes me wonder what I’ve been doing 
for the last 25 years because it’s really tragic. There’s a hell of a lot of misery out 
there.
Tansey: Can I just say it’s not for want of trying to find them, nor for inviting 
them.
Eastwood: Oh I know. 
Tansey: I just want to put that on the record.
Eastwood: Yes, sorry, anyway I’m digressing slightly.
Follett: Back to the treatment.
Eastwood: Bright white light via the eyes is the most effective treatment for 
the majority of people with SAD, certainly in the UK. The problem with it is 
compliance, using it enough throughout the winter. Medics will tell you that 
with any treatment, the biggest problem is compliance. However, it is often 
difficult to use enough light treatment to stay well throughout the winter. We 
all say how wonderful it is and that it’s only 30 minutes at the beginning of the 
day but I’m afraid that’s not the reality for most of us. People with full-blown 
SAD need at least two hours’ treatment every day with 10,000–20,000 lux and 
even that may not be enough.107
Those people who find that light is not enough or want a back-up, supplement 
it with whatever drugs are recommended or available. Bupropion (Wellbutrin), 
which is the main drug of choice for SAD in the USA, is also prescribed in 
most north European countries.108 However, in the UK, bupropion is only 
licensed as Zyban to help people give up smoking! My GP has to go along to 
the local primary care trust (PCT) every few months and make a case as to 
107  Ms Jennifer Eastwood wrote: ‘We need to use it every day (the occasional day off is usually okay) from, 
in some cases, September to April.’ Note on draft transcript, 31 January 2014.
108  Bupropion was patented in 1969 by Burroughs Wellcome (Wellcome Foundation – which became part 
of what is now GlaxoSmithKline). It was approved by the FDA in the USA as a treatment for the prevention 
of SAD in 2006. For a review of the treatment see, for example, Niemegeers et al. (2013). See further 
comments on Wellbutrin by Professor Norman Rosenthal on pages 42 and 48.
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why I have to have bupropion when there are so many lovely antidepressants 
around. As you can see, I’m someone who has learned the system and jumps up 
and down till she gets what she wants, but the majority of Brits don’t and they 
put up with what they are told. However, there are a number of other drugs, 
in particular selective serotonin reuptake inhibitors (SSRIs), many of which are 
very effective.109 They came on the market about the same time as light therapy 
so the combination of them was pretty fantastic, certainly for the psychiatric 
element of SAD. Personally, I don’t think drugs deal with the real biological 
depth of SAD, the cognitive and vegetative symptoms that make you only a 
fraction of yourself during the winter. I’ve studied this for many years in myself 
and a selected group of people that I’ve kept an eye on over the years and there’s 
something about light that, if you use enough of it, it does the trick.
The only thing that really gets there, as Norman says, is going to the Canaries or 
somewhere much nearer the Equator. If I’d known about SAD earlier, I would 
have left the UK and never come back in the winter. The trouble is that by the 
time you find you have SAD, you’ve made a life here. It is purely and simply 
about moving nearer to bright daylight and long daylight hours.110 I don’t know 
anybody who has been diagnosed with SAD that is any different. 
Those are basically the treatments. We’ve tried pretty well everything, including 
complementary treatments, though few of the therapists will ever engage in any 
research, they all just come along and think they can cure you. Psychotherapists 
are the worst; the ones I’ve met have almost all said: ‘Oh I’m sure we can cure 
you of this’, and I’ve never known anyone to be able to do it. I’ve had about 20 
years’ psychotherapy and it was a great help but it doesn’t treat SAD. So that’s it.
Follett: Well, we’ve got other people here in the room who undertake SAD 
research: Ilana and Peter Crome, for example, who are researchers. 
Professor Ilana Crome: We are here as very long-standing friends of Norman. 
I am a psychiatrist and I did work with Stuart Checkley at one time but I 
moved on into addiction psychiatry in the mid-1980s. But I will say a few 
109  For the drug treatment of SAD, see, for example, Winkler et al. (2010). For a discussion of SSRIs and 
depression, see comments by Professor Philip Cowen and others at the Witness Seminar on drugs affecting 
5-HT systems (Overy and Tansey (eds) (2013), pages 115–22 passim).
110  Ms Jennifer Eastwood wrote: ‘Many of us manage a few weeks’ holiday in the sun but the problem is 
that when you return to the UK, the symptoms come back after 3–4 days so, in theory, you need to move 
south by the end of October and stay till March at earliest, as the nineteenth-century psychiatrist Esquirol 
advised. This is not conducive to family life, work etc.’ Note on draft transcript, 31 January 2014.
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things. Education is a big issue that has come up, I think that Jennifer and 
Norman have alluded to that, but medical students get very little education in 
psychiatry generally throughout their training and I don’t think SAD would be 
high on the agenda of any training scheme because there are many people who 
say there are a lot more disorders that a medical student needs to be taught. So 
I think that is one reason why you would be confronted by psychiatrists and 
other medical practitioners and their teams who know very little about it and 
lack the confidence to undertake or suggest any treatment. Doctors are driven 
by NICE and if NICE is not going to recommend it, it’s a real issue. So there 
are a lot of aspects that can lead to the fact that patients seeking help won’t get 
the right kind of help. My own interest is psychiatric co-morbidity so what I 
haven’t heard from anybody is what the other psychiatric disorders that may be 
associated with SAD could possibly be because there is a great deal of physical 
and psychiatric co-morbidity in individuals who have psychiatric disorders. 
That’s something of interest to me. Finally, I’d just like to say, I don’t know 
what the relevance in terms of aetiology of SAD may be for affective disorder 
generally or other co-existing disorders. So maybe somebody can answer that.
Follett: Let’s first go to Jo before we come to answer your question.
Arendt: I was just going back very briefly to treatment, and to ask Al in particular: 
you know that the melatonin agonist agomelatine is actually registered for 
Figure12: Professor Ilana Crome
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depression.111 Do you think there is an element of that in the effects of your 
treatment with melatonin via 5-HT
2C
 receptors?112
Follett: And what’s the history of this? 
Lewy: Servier (by the way full disclosure, I consult for Servier) has a melatonin 
agonist that they’ve patented (agomelatine) that shifts circadian rhythms just 
like melatonin, but also affects some serotonin receptors. The thinking of the 
Servier people is that agomelatine has a dual mechanism for its antidepressant 
effects, that both its circadian phase-shifting effect is important, but also its 
serotonergic effects.113 Now Servier is using their drug, as Jo mentioned, for 
non-seasonal major depressive disorder, and I think it’s sold in 75 countries 
around the world. Is it in the UK?
Arendt: I believe so.114
Lewy: It is not sold in the USA or Canada. In 2009 we published a paper – Jon 
Emens is the first author – showing that 17 non-seasonal major depressives 
had a correlation between the amount of phase delay in the melatonin onset 
relative to the sleep-wake cycle and the increase in their depression ratings.115 
Then in 2010, three groups published further findings, including successfully 
treating non-seasonal depressives with melatonin to advance their body clock.116 
Nothing more has appeared since 2010, and I’m not sure what the reason is. 
In any event there may be a component of circadian misalignment in other 
disorders besides SAD, such as non-seasonal major depressive disorder. Our 
latest finding, which is due to appear in early 2014, is that anxiety symptoms 
in SAD seem to be related to circadian misalignment.117 And the Servier folks 
111  de Bodinat et al. (2010). 
112  The British usage of the term 5-HT and the American usage of the term serotonin for the same 
compound has been maintained throughout the transcript.
113  Professor Alfred Lewy added: ‘To the best of my knowledge, melatonin only has the phase-shifting 
effect and not the effect on serotonin receptors.’ Note on draft transcript, 24 February 2014. For additional 
discussion of agomelatine, see the comments by Professor Daniel Hoyer at the Witness Seminar on drugs 
affecting 5-HT systems (Overy and Tansey (eds) (2013), page 114).
114  Agomelatine, marketed as Valdoxan, was approved for use in the European Union in 2009. For a review 
of its antidepressant efficacy, see Taylor et al. (2014).
115  Emens et al. (2009).
116  Buckley and Schatzberg (2010); Rahman, Kayumov and Shapiro (2010); Hasler et al. (2010).
117  Lewy et al. (2014). 
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also find that agomelatine is effective in anxiety. So there’s a lot more research 
that needs to be done on the circadian misalignment component in various 
psychiatric disorders and on what sort of specific features it is closely related to. 
Is it depression? Is it anxiety? Both? There are some other features of psychiatric 
disorders that may have a circadian misalignment component as well.
Lucas: Sticking on the therapy question. The defining feature of SAD is that 
light is the most effective therapy, but I wonder how well defined the light that 
you need is? To be fair to NICE, I’m not sure that I could tell for sure what the 
efficacy of any given light would be. We talked about 2,500 lux. I’m sure I could 
give you a 2,500 lux light that wouldn’t be very effective if it did not contain 
the right wavelengths.
Follett: Do we know about whether there are particular aspects of the spectrum 
that are more effective or less effective? In developing light therapy, you must 
have tried a number of different lights?
Rosenthal: If I can just follow up on a couple of threads here. The first is 
treatments of SAD other than light therapy and, in fact, clinically speaking, many 
antidepressants are very effective, including the serotonergic antidepressants, 
the selective serotonergic reuptake inhibitors, and the serotonergic and 
norepinephrine reuptake inhibitors. Wellbutrin, which you’ve heard about, 
is a norepinephrine and dopamine reuptake inhibitor, so all of these three 
major neurotransmitters that have been implicated in depression are helpful 
when they’re tinkered with by the various antidepressants in people with SAD. 
However, this has not been done in large-scale studies. When we came to look 
at Wellbutrin as a prophylaxis for SAD, I was a consultant to GlaxoSmithKline, 
which was the distributor of Wellbutrin (which has subsequently gone off patent 
in the United States). We had to go before the FDA and get authorization to 
regard SAD as a distinct treatment entity that was eligible for being studied 
in its own right, so that if researchers were to show an effect of a drug, they 
would then be able to advertise it specifically for SAD.118 Up until that time 
SAD had been lumped together with the rest of depression and therefore 
there was nothing in it for any of the pharmaceutical companies to study it 
selectively and specifically. So that’s why these other companies never had done 
that. But the FDA said: ‘Yes, SAD is a specific distinct entity. You can study it 
and you can advertise specifically for SAD and you can do it prophylactically’, 
118  Wellbutrin was approved by the FDA for patients with SAD in June 2006. See also comments on pages 
42 and 44.
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which was a big step. But the serotonergic drugs do work practically speaking. 
Now to get back to Rob’s excellent point earlier: light is working on a lot of 
things other than the circadian system and that’s really important to note. For 
example, the retinohypothalamic tract that goes to the pacemaker (SCN) works 
via glutamate, and one of the big stories in modern antidepressant treatment 
is the use of ketamine for highly refractory depressions.119 And ketamine is 
known to work on glutamate receptors. In addition, the pacemaker is gated by 
serotonergic inputs so when you’ve got something that’s as important as light 
and dark that we’ve evolved with over all these millennia, you can imagine 
that light is having many, many effects. As Jo Arendt and I were talking about 
in the break, people placed in light are immediately activated. You know if 
you keep bright light on it will be hard to go to sleep at night. Now that’s too 
quick to have a pacemaker effect, presumably it’s just an activating principle. 
That’s why they have bright lights in supermarkets because you’ll buy more 
stuff because you get activated. So what I’m really saying is light is doing a 
lot of things. Now clinically this has been exploited in terms of premenstrual 
syndrome. My colleague, Dr Barbara Parry, who worked at the NIMH, has 
shown that premenstrual syndrome can be prevented and treated by the use of 
light, including evening light.120 Likewise, Dr Raymond Lam up in Vancouver 
has shown that bulimia can be strongly influenced by the use of light.121 Now 
both of these may be being helped through serotonergic influences of light. For 
example, there’s a Lancet paper where they cannulated the jugular vein of normal 
volunteers and measured serotonin output coming from the brain and showed 
that, in normal volunteers, serotonin concentrations in blood were highest on 
the brightest days.122 But there are so many neurotransmitters that I’m sure we 
have hardly even touched on the full spectrum. I think we probably just have 
seen the tip of the iceberg because it’s what we studied, but there are probably 
a lot of other things that are influenced by light. The other thing I want to 
mention just getting back to the DSM-V criteria is that they require you to have 
SAD only if there’s complete remission or hypomania in the summer whereas 
many, many people with SAD do not completely return to a normal mood in 
the summer time. You can comment on this maybe, Jennifer, but a lot of people 
119  See, for example, Salvadore and Singh (2013); Browne and Lucki (2013). 
120  See, for example, Parry et al. (1987). 
121  See, for example, Lam (1989); Lam et al. (2001). 
122  Lambert et al. (2002). 
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have got a sort of chronic low-grade depression that gets much worse in the 
winter time and clearly all of the work that’s been done in SAD is applicable to 
that group of people as well. They should not be excluded.
Hanson: I would like to add that the awful summer of 2012 was a very good 
example of what you’ve just been speaking about. We had continuing press 
interest, rare in summer, and also a lot of reports from sufferers that their 
symptoms had either not gone away that summer or that they’d had serious 
lapses.123 We’re starting to feel in SADA that the division into seasons is a bit 
arbitrary and doesn’t fully explain the nature of the condition.
Rosenthal: This is a very, very important point because the syndrome is not just 
a seasonal syndrome, it’s a light deficiency syndrome, and what we have seen 
with global warming and summers being intensely hot in the United States is 
that a lot of people with SAD are staying indoors in the air conditioning and 
putting their blinds and their shades down so that the sun doesn’t overheat 
the interiors. And in doing so are getting light deprived and paradoxically are 
having winter type depressions in the summer because of global warming.
Barksfield: Yes, Norman, we’ve seen the same thing and what we’ve found as 
well is that a lot more office buildings are being built with tinted glass so a lot 
of people, even though they’re sitting next to a window working, even if it’s 
summer, they’re still finding the symptoms or still experiencing the symptoms 
of SAD because they’re still not getting any light during the summer either. So 
we have found as a company it’s much less seasonal and more of a year-round 
thing. 
Hanson: I’d like to add that we’re particularly concerned about children and 
young people. We’ve had quite a few people writing into us about the fact that 
they notice when they go into their children’s schools that these days they’re 
working at screens in darkened rooms with the curtains drawn, blinds down, 
and so on. The whole question of environmental light and its relationship 
to health is something that we just don’t seem to take on board in the UK. 
We may be laying trouble for ourselves. I think they are much more aware 
of environmental light in the workplace in Germany, for example, and in the 
Scandinavian countries. We’re behind the times in this respect and should be 
addressing the issue. 
123  In the UK, the summer of 2012 had below average temperatures for June, July, and August, was the 
wettest since 1912, and had 82 per cent of the normal sunshine; see the statistics at the Met Office website 
at www.metoffice.gov.uk/climate/uk/2012/summer.html (visited 17 March 2014).
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Lewy: I agree with what’s being said about light in the workplace and in 
the home, but generally outdoor light has to be experienced outdoors to be 
chronobiologically influential. The window acts like a point source for sunlight, 
and given the inverse square law between experienced light intensity and the 
distance your eyes are from the light source, unless your nose is almost pressed 
up against the window pane and sunlight is directly streaming in, you’re 
probably not going to get bright enough light indoors to do much to your 
body clock. But getting back to a couple of other points here: I agree with 
Norm that there is an energizing effect of sitting in front of a light box.124 I 
think we all agree there. But until a specific mechanism is identified, I have to 
put that effect in a slightly different category than the phase-shifting effects of 
light. And so I tell my patients: ‘You need the light in the morning or a few of 
you need it in the evening but don’t do it at both times. More light does not 
necessarily mean a better effect. If you like the immediate effect of the light 
and you really want more light, add it in the middle of the day, in the dead 
zone of the light phase response curve where it won’t counteract the phase-
shifting effect of light that is important for its antidepressant mechanism.’ But 
getting back to Rob’s point about what kind of light: the light intensity should 
ideally be between 2,000 and 10,000 lux. I think we’ve pretty much capped it at 
10,000 lux, because we’re still a little concerned about doing damage to the eyes 
at higher intensities. Some people need to sit in front of it, at least to start out 
with, for 2 hours a day, ideally shortly after awakening, and then they can cut 
down the duration to 20–30 minutes once they respond. The eyes have to be 
open, of course. We don’t have them stare at the light; we have the light coming 
in from an angle, from the side or, if you’re reading and your head is tilted 
down, from above. So that’s been the standard for a couple of decades now. 
With regard to the light wavelengths, which you are, of course, an expert on, 
Rob, George Brainard and I published the first study of different wavelengths 
suppressing melatonin in humans in 1985 and we found, in this early study, 
that the greatest suppression of melatonin production was at 509 nanometers, 
which is blue-green light.125 And, of course, the melatonin suppression test tells 
us how the light’s going to be effective in causing phase shifts. We’re not saying 
the suppression of melatonin is necessarily involved in anything, except telling 
us that this intensity and wavelength composition will be effective when used 
in the morning to phase advance the clock, or in the evening to phase delay 
124  Lewy and Sack (1986).
125  Brainard et al. (1985).
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the clock. Now perhaps, Rob, you could explain to us what’s been happening 
with the excellent work of you and your colleagues on melanopsin and which 
wavelengths are most effective in stimulating melanopsin, which is the most 
important photoreceptor for these effects.126 But before getting into that I think 
there are studies with green light, which is close to 509 nanometers, and there’s 
a controversy over pure blue light being bad for the eyes, that you might want 
to comment on.
Lucas: Yes, I’m happy to comment. Jo should also speak about her action 
spectrum for melatonin suppression, which was published in 2001, is that right?
Arendt: Exactly the same day as …
Lucas: As Brainard’s, exactly yes.127 [Laughs] 
Arendt: I think there was some collusion of journal editors there.
Lucas: Okay, at one level this comes to very fundamental questions of mechanisms 
and how light is detected because, of course, the spectral sensitivity of rod and cone 
photoreceptors is very well established and known for a long time, and if they were 
the only players in the system you could make some pretty reasonable assessments 
of what wavelengths of light would be important. So the discovery that there’s 
an additional photoreceptor system involving melanopsin and these intrinsically 
photosensitive retinal ganglion cells (ipRGCs) is an important underpinning 
science for this field. In terms of spectral sensitivity of that photoreceptor, some of 
the earliest evidence that this was a sort of a blue light photoreceptor came from 
work in retinally degenerate (RD) mice in the late 1990s. Ebihara’s lab published 
some work in RD mice, which have almost no rod and cone photoreceptors left 
and looked at circadian phase shifting and reported a maximal spectral sensitivity 
at 480 nanometers.128 That’s important because none of the mouse photoreceptors 
had a peak around then. But that work was not as influential with hindsight as 
maybe it should have been because there was other work on RD mice reporting 
a different spectral sensitivity, leaving the literature a bit confusing. In 2001, we 
published a paper showing that the pupil light reflex in mice lacking rods and 
cones had peak sensitivity around 480 nanometers.129 And since then that figure 
126  See Lucas et al. (2014). 
127  Brainard et al. (2001); Thapan, Arendt and Skene (2001). 
128  See, for example, Yoshimura and Ebihara (1996). 
129  Lucas, Douglas and Foster (2001). 
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has proved to be retained for melanopsin in all species looked at so far. So in 
2002, David Berson reported the first description of these ipRGCs in Science and 
he showed in rats that they had a peak sensitivity around 480 nanometers130 and 
subsequently Dennis Dacey and Paul Gamlin showed in primates that they were 
480 nanometers131 and Paul Gamlin showed for pupil light reflex for humans 
that there was a 480 nanometer component.132 Then just last year we showed 
for human melanopsin protein expression in vitro that it had peak sensitivity at 
480.133 So I think most people now would say that this melanopsin photoreceptor 
peaks in the blue part of the spectrum but because of the way the opsin works 
it does, of course, absorb over quite a wide wavelength range so there’s nothing 
magic necessarily about blue, it’s just the blue is slightly more effective than green, 
or violet for the melanopsin system. Now, relating that to Seasonal Affective 
Disorder, or indeed to phase shift in the clock, or to melatonin suppression, we 
have to consider the possibility that it’s not just melanopsin that contributes to 
these responses but also potentially other photoreceptors. We know that this is true 
from animal experiments, from lots of people’s work that the ipRGCs respond to 
light both because they have melanopsin and because they receive input from 
rod and cone photoreceptors. I think it’s fair to say that at present we aren’t sure 
as a field exactly what determines the relative reliance of downstream responses 
on those spectrally distinct inputs. Therefore it’s hard to be sure a priori what 
wavelengths your biological system would be responsive to under a particular 
set of circumstances. So as part of that, of course, one would really like to know 
what’s the spectral sensitivity of biologically relevant events in humans, and it 
would be great to know what that was, for example, for treatment of SAD. Jo’s lab 
and Brainard looked at this for melatonin suppression and perhaps I should pass 
the microphone onto you, Jo, for that. 
Arendt: We played around with different intensity and spectral characteristics 
of light in the 1980s and 1990s. The lead person on the action spectrum project 
was my colleague Debra Skene with our PhD student Kavitha Thapan, and I 
was just the Principal Investigator. We found a peak of melatonin suppression 
at 465 nanometers in our first shot at this, but that was then adjusted by further 
130  Berson, Dunn and Takao (2002). 
131  Dacey et al. (2005).
132  Gamlin et al. (2007); McDougal and Gamlin (2010). 
133  Bailes and Lucas (2013). 
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points on the curve to very close to 480.134 This also appeared to be the peak for 
phase shifting and alertness in our work and that of others.135 My interest in this 
is, of course, how can you make use of it in real life and I am much too old to 
wait for all these mechanisms to be sorted out. In our group Philips Lighting 
have worked very hard with Debra and Benita Middleton and colleagues to look 
at ‘blue enriched’ light compared to standard white in a variety of circumstances 
in old people’s homes, for example.136 But we have not studied SAD because we 
don’t work at the moment with psychiatric hospitals. From the literature on 
blue enriched light as a treatment for SAD, compared to standard white light, 
it is difficult to find a consensus. In a polar work environment some people 
don’t like it in my experience. We carried out long-term light supplementation 
at Halley (75˚S) using bright, standard white light, compared to blue enriched 
light, initially 10,000K and the following year 17,000K (Philips Lighting). We 
looked at circadian phase, sleep and ‘alertness’ in winter, increasing the personal 
light exposure from the maximum of 500 lux, which was the most anybody 
previously saw on base in the winter. If you raise the light intensity such that 
people experience 2,000 lux maximum at some point during the day it makes 
a big difference. We get a circadian advance using 6-sulphatoxymelatonin as a 
marker and much improved sleep from the point of timing and from the point 
of view of efficiency. But we found very little difference between the standard, 
bright white and blue enriched light, the exposures in lux being approximately 
equivalent.137 So I would say that it was not worthwhile yet choosing blue 
enriched light until we know a lot more.138 
Rosenthal: Just a couple of points. With Dan Oren in our group, we did a study 
of red versus green light in the 1990s. We found that green was better than 
red for SAD, which is as one would expect even using just the conventional 
134  Brainard et al. (2001); Thapan, Arendt and Skene (2001).
135  See, for example, Lockley, Brainard and Czeisler (2003); Revell et al. (2005); Lockley et al. (2006); Revell 
et al. (2006).
136  Professor Josephine Arendt added: ‘….[and] with Derk-Jan Dijk and co-workers to look at office workers 
(Viola et al. (2008)), with myself, Benita Middleton and Antarctic base doctors to optimize lighting for sleep 
and circadian phase on an Antarctic base (Francis et al. (2008); Mottram et al. (2011); Arendt (2012)).’ 
Note on draft transcript, 29 January 2014.
137  Mottram et al. (2011).
138  Professor Josephine Arendt added: ‘ … or indeed green light which is also in contention…There is 
however some evidence that monochromatic blue or green light can be effective with much lower exposures 
than standard white.’ Note on draft transcript, 29 January 2014.
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photoreceptors.139 That’s the one point that I’d like to make. The other is that 
we did look at a polymorphism of a gene involved in melanopsin and found 
that in our SAD patients there were significantly more of a certain variant of 
that polymorphism than in healthy controls.140 However, it only explained five 
per cent of the SAD patients, so that raises the possibility, or probability, that 
SAD may be multiply determined by many different genes that influence the 
circuitry between the retina and the brain. There must be many junctures, 
many neurotransmitters, many receptors, any of which might be important in 
that process. I also wanted to comment on the ‘not just one receptor’ that Rob 
raised.141 Dan Oren and a colleague have just published in the American Journal 
of Psychiatry a paper wittily titled ‘SAD and the not-so-single photoreceptors’, 
which talks about different possible mechanisms whereby light might be 
working other than melanopsin, including an ingenious possible humoral 
mechanism involving some kind of portal system that Oren has been looking 
into.142 And it’s very ingenious, I hope it’s correct. But anyway that’s a nice article 
for people to be aware of. The point that I wanted to follow up with what Rob 
had mentioned earlier is that – and I think if I’m quoting you correctly – you 
had said that you’re not all that surprised that the NICE group didn’t conclude 
that light is effective given the multiplicity of different interventions.143 Is that 
correct? 
Lucas: No, no, I guess what I meant to get across is that one way that you could 
explain their decision is not their doubt that light is effective, but how would 
you define an effective treatment? That’s what I was getting at. This comes really 
to talk a bit about what you were talking of, Jo, about your blue enriched light, 
and at some point you have to talk about light in quantitative not qualitative 
methods.
Rosenthal: Well, I think you could say, and I’ve looked at this to try and come 
up with a sort of standard recommendation that would encompass most of these 
studies, that they’re white light by-and-large, almost all of them. They have light 
boxes or light fixtures that are about a foot square in terms of their illuminated 
surfaces, and size is very important in terms of the surface area that the light is 
139  Oren et al. (1991). 
140  Roecklein et al. (2009). 
141  See page 52. 
142  Oren, Koziorowski and Desan (2013). 
143  See page 48. 
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coming from, not just the fact that you can measure 10,000 lux at one point 
because nobody’s sitting just at one spot without moving their head around. So 
the bigger the surface the more forgiving it is of people’s moving around, which 
they will normally do. So I’ve said one foot square, white light between 2,500 and 
10,000 lux and that’s what most controlled studies that have had positive effects 
have found. I think that it’s important to recognize the common thread between 
these studies, and not to say: ‘Well, because they all differ from one another by 
small degrees here or there, you have to chuck out the entire canon of literature 
on the thing.’ In terms of blue light, it’s been marketed especially because of the 
melanopsin tie-in, but to Jo’s point, there is actually no good evidence that it’s any 
better than white light and there are no good efficacy studies out there indicating 
that blue light is the thing to use. There’s also a blue light toxicity literature that 
people as distinguished as retinal expert, Dr Charlotte Remé in Switzerland, have 
expressed a lot of concern about.144 Also, the French equivalent of the Food and 
Drug Administration has actually expressed concern even about white light LEDs 
being the light source of choice in indoor environments because of the amount of 
blue light emanating from those LEDs. 
Follett: I gain the impression that over the years we’ve all carried out a number 
of experiments and there is no magic bullet. White light is about as good as you 
can get and there may be some additive if not synergistic effects by adding some 
other pharmacological agents. 
What I’d like to turn to, if I could, is the last question: What status have these 
therapies in terms of clinical diagnosis, psychiatric practice, health insurance 
etc? So can we now go backwards, not to what the position is now, but what, 
over the 20 years since all this was first uncovered, has been the response of (a) 
the psychiatric profession and (b) of the major drivers on providing facilities 
and drugs? Is it a good story or less than good?
Lewy: This is something I would like Norm to comment on. He has a lot of 
information on this. There was a lot of resistance in the early days to recognize 
SAD as a disorder and insurance companies would not reimburse for a light 
fixture.
Follett: Are we talking 25 years ago?
Lewy: Yes, in the 1980s. But over the years, in my experience, insurance 
companies, with a letter from the physician, will reimburse about 50 per cent of 
144  See, for example, Grimm and Remé (2013); Ebert et al. (2012).
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the cost of a light fixture. And it is cost effective when you consider how much 
a prescription for antidepressants would be for five months, year after year. And 
a light fixture lasts a long time. 
Follett: Roughly how much does one of these one foot square light boxes cost?
Barksfield: £150.
Follett: Good Lord, that wouldn’t pay for your average medic in this country 
for an hour. 
Rosenthal: I think that you make the point brilliantly. It’s such a small cost and 
it’s a one-off cost and it helps people every single day through the winter months. 
It’s ridiculous that it’s not reimbursed. In America I would say a significant 
percentage, though a minority, succeed in getting insurance, and in my book I 
have included a sample letter to the insurance company to help providers help 
their patients get insurance reimbursement (Figure 13). 
But I just want to flag what I thought was a brilliant comment that you made that 
we have to find an MP with SAD.145 It reminds me of the old joke about when 
a secretary was being hired and some very ill-qualified candidate was selected 
and somebody said: ‘Why did you select her?’ And the personnel manager said: 
‘She’s the boss’ niece.’ And that’s really how business gets done unfortunately. 
I think that somebody who has the ear of law makers or policy makers is what 
is needed here because science hasn’t done it, clinicians haven’t done it, writing 
books hasn’t done it. I think other mechanisms need to be invoked in order 
to get help for the millions of people who are suffering grievously from this 
condition. That’s why I’m so grateful for this symposium and anything that 
it does to further the help for those people who are not being treated and not 
getting light, not getting what can make them function all year round. 
Follett: One of the other great ways that pressure could be applied is, of course, 
if the funding agencies support research in this field very strongly. They have a 
great impact because they have access to government. Historically, how has the 
NIMH or the NIH looked at grants? How have the MRC and the Wellcome 
Trust looked at funding? You must have a sense historically what’s happened?
Rosenthal: In the United States there’s an intramural programme that’s a 
concentrated programme in Bethesda, Maryland, where Al and I and Tom Wehr 
145  See the comment by Professor Sir Brian Follett on page 28. 
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Figure 13: Sample letter for insurance reimbursment.146
146  Rosenthal (2013), page 152.
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and Fred Goodwin did our work. There was a golden age where we were very 
well funded. Al can tell you about the extramural programme of the NIMH.
Follett: I hear it from every clinician from across the Atlantic. 
Rosenthal: There was a golden age and it’s passed. But I think that currently 
funding for light therapy and SAD research is probably very attenuated from 
where it was in its hey-day. I can’t comment about the UK.
Follett: Let me ask you a bit further. Is it that money historically has come out 
of this area and gone into other areas of psychiatry or is the whole of psychiatric 
research underfunded? I can conceive of a situation where historically, with the 
rise of molecular biology and all the positives it brings, in some ways quite large 
areas have been squeezed out of the funding model. We’ve certainly seen it here. 
Rosenthal: The pie has gotten smaller. It’s much harder to get funded for 
anything in some areas, including psychiatry, seven per cent of grant applications 
get funded. It’s very discouraging; you would know better than me, Al.
Follett: Does that suggest, Al, therefore that historically many clock biologists 
have not been drawn into this area of science?
Lewy: Governmental funding is just one leg of the funding stool. Another major 
leg is funding by pharmaceutical companies. However, it is difficult to patent 
light, although one of our colleagues has a light patent, and so you can’t interest 
industry in supporting this work. So I’m just actually amazed that it’s gotten 
this far without industrial support. It did have a golden age at the NIMH when 
Fred Goodwin went on to become the director.147 After he left, the succeeding 
directors, for whatever reason, have focused on other areas. And hopefully 
both intramural and extramural funds will once again be directed more to this 
research, because there are so many important things for us to figure out. In the 
example of circadian misalignment, we don’t know which rhythm (or rhythms) 
represented by the DLMO is misaligned with what other rhythm (or rhythms) 
related to the sleep-wake cycle that is actually causing SAD, or at least this 
component of SAD, and which needs to be corrected to treat SAD. Gerald 
Lincoln might have some ideas about thyroid hormone because it is so important 
in his work. Cortisol, the stress hormone, has a circadian rhythm, and I would 
think that’s a likely candidate. I don’t think it’s melatonin. I want to be very clear 
that the melatonin rhythm is an important marker and dependent variable, and 
although you can give exogenous melatonin, especially in low doses, to shift 
147  Professor Frederick Goodwin was Director of the NIMH from 1992 to 1994.
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the body clock (so that it can be an independent variable), the jury is out as 
to whether or not endogenous melatonin has an important function.148 In any 
event, I don’t think that the light is acting as an antidepressant by affecting the 
endogenous melatonin rhythm per se. 
Arendt: You can live without melatonin, you can sleep without melatonin – 
but you sleep better with it. In general I agree with you.149 But what I would 
like to say is that the Dutch group working with Serge Daan have looked at 
the intrinsic circadian period of SAD patients and of normals and they found 
that the SADs were no different from the normals in the various rhythms that 
they looked at, except for a reduction in the amplitude of the core temperature 
rhythm.150 So I’d really like to hear your comment on that.
Follett: To those of you outside this scientific argument, might I explain? The 
group led by Serge Daan – one of the cleverest clock biologists alive – has 
discovered that the internal circadian system of SAD patients appears to be the 
same as normal patients. That may still be okay because it isn’t actually what 
your internal clock may express, it’s where it’s located relative to the light-dark 
cycle, which historically appears to be at least Al’s basic hypothesis on what he’s 
changing when he gives either an early morning light pulse or a late afternoon 
melatonin pulse. 
Lewy: I agree with your explanation; that’s a reasonable explanation to 
understand the realm of possibilities here. The study by the Dutch workers, I 
think they studied seven patients.151 They averaged their data and compared it 
to the average of normal controls, so if there was a phase-advanced subgroup 
in the patients, this would have brought the average of the SAD patients closer 
to that of the controls. You would really have to look and see if there was 
148  Professor Lewy added: ‘I have, however, proposed a few ideas over the years for possible functions of 
endogenous melatonin in humans (Lewy (1983a); Lewy et al. (1994); Lewy et al. (1992); Lewy (2007); 
Lewy (2013)).’ Note on draft transcript, 14 February 2014.
149  Professor Josephine Arendt wrote: ‘Perhaps I should specify pineal melatonin. Treatment with quite large 
amounts to increase duration (supraphysiological) does not, in my experience, lead to depression (Arendt et 
al. (1984)). In general I agree with you. However, when it is correctly phased I think it reinforces what has 
been called “darkness physiology”. To me its primary function is to convey information about daylength and 
it has modulatory effects with respect to the circadian system.’ Note on draft transcript, 29 January 2014.
150  Koorengevel et al. (2002). The paper is from Daan’s group but he is not a co-author.
151  Koorengevel et al. (2002). 
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this subgroup, as we have found in our studies.152 So that’s how I’ve always 
understood the Dutch study. It’s a very difficult study to do, and I don’t believe 
it’s been attempted since it was published 12 years ago.153 
Follett: Gerald, where do you come in from the point of view of ‘seasonality’?
Lincoln: I think we should be able to learn lessons from what we’ve discovered 
in the last ten years about the basic mechanisms operating in the pituitary 
and hypothalamus that govern seasonal timing. It seems that the photoperiod 
transduction pathway involving melatonin is a separate system, distinct from 
the core timing process that goes on in the brain and peripheral tissues to 
regulate seasonality. Many organisms are non-photoperiodic and yet express 
robust circannual rhythms. The neuroendocrine and anatomical interface 
where endogenous timing and photoperiod control comes together is really key 
to our understanding. Long-term time keeping appears to be based on changes 
in the availability of thyroid hormones, critical in the control of cell biology, 
and governed by deiodinase genes activating locally in the hypothalamus.
This is timed by the way in which the melatonin signal that encodes photoperiod 
regulates thyroid-stimulating hormone (TSH) production from the pituitary 
gland. Unexpectedly, and in a most remarkable way, the TSH doesn’t act 
peripherally, as for the normal control of the thyroid gland, but acts locally 
within the adjacent hypothalamus to alter the deiodinase gene systems and hence 
seasonal biology. One gene (Dio2) up-regulates and one (Dio3) down-regulates 
thyroid hormone availability – shifting the physiological and behavioural state 
from negative to positive or vice versa, driving the seasonal cycle. 
Subjective Summer is the time when thyroid hormone biological activity is 
maximal, and on come all the proactive cellular mechanisms of neurogenesis, 
growth, replacement of tissue – it’s like a ‘metamorphosis’. There are remarkable 
parallels with frog metamorphosis. The change from tadpole to adult is also 
dependent on the local production of active thyroid hormones in the tissues 
where the transformations in cell biology actually happen. So here we have 
evidence that every summer seasonal mammals go into a high thyroid hormone 
state in the brain with a major impact on physiology and behaviour. In the 
152  Lewy et al. (1987a); Lewy et al. (2006).
153  Professor Alfred Lewy wrote: ‘Also, related to what Brian has pointed out, there need not be a normative 
difference between patients and controls, as long as patients are different when depressed compared to when 
they are euthymic, an ipsative difference (Lewy et al. (1987b)).’ Note on draft transcript, 14 February 2014.
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winter, the systems are globally shut down for the very logical reason – to 
conserve energy. So here is a helpful hint as to the fundamental nature of the 
control of seasonal transitions that may underlie the rhythmicity of SAD.154
Dixon: I’m afraid it doesn’t really follow on exactly from what we just heard 
but for me this is such a fascinating symposium; to hear about this incredibly 
complex and imaginative and lengthy process that the scientists, clinicians, and 
patients have all been involved in, which for me is like this incredible case of 
how do you create a disorder? You’ve got to put it a particular way. How do you 
create a belief in a real disorder that scientists and doctors and patients and the 
general public and journalists believe in and recognize and can all talk about? 
And that’s what we’ve been hearing, this amazing sort of sociology of medicine, 
in a way, in practice over the last 30 years and it’s incredibly complicated. It’s 
about animal behaviour; it’s about circadian rhythms; it’s also about the thing 
that Professor Rosenthal became very passionate about –suffering; it’s about 
real human beings having real suffering and frustrations of trying to create 
knowledge and treatment around that. So that’s just a comment that it has been 
really fascinating for me to hear all about this. I wanted to ask a question which 
was more about how the social and cultural history of this, you might say, has 
played out over the last 30 years. I’ve become aware of SAD during my lifetime, 
154  See Hazlerigg and Loudon (2008); Hazlerigg and Lincoln (2011); Stevenson and Prendergast (2013).
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probably 15 years ago. I started hearing friends say that they had SAD. These 
people kind of self-diagnosed so it’s an amazing achievement. Around the world 
people are self-diagnosing themselves with this condition. It doesn’t happen 
very often. And obviously we have experts here who run a patients’ association 
in this country. So I wanted to ask about the social and cultural history of it: 
Are there still a thousand people a day contacting SADA or has it kind of passed 
its peak in terms of something that’s created a great deal of public recognition? 
Eastwood: I confess that I’ve taken a back seat in SADA for the last 10 years 
and I’ve only just become involved again. We had 15 intensive years of non-stop 
work and media interest, and there was a point at which I felt that every taxi 
driver in London knew all about SAD, the mechanism, how it was treated, and 
pretty well everybody said: ‘Oh I know how that feels’, but they don’t. It was 
easier to get through to the media and make SAD generally known about than 
get the medical profession to take an interest. It still is, I think.
I take some of the blame for this on behalf of SADA. In the early days, we 
tried to get enough good psychiatrists to run clinics in tertiary care in all areas 
of the UK and not just the two London ones. Some SADA members went to 
their local psychiatrist and, by the time they’d interested them in SAD, they 
were often prepared to see more patients. It was almost socially engineered in a 
way; we had our own tame psychiatrists that we could rely on to test, diagnose, 
and treat SAD so maybe it is not surprising that too few medics know much 
about it.155 
There’s something about SAD that just seems to be sad! I know that sounds 
meaningless in the scientific sense but, of all the hundreds of thousands of 
people I’ve heard from over the years, I can identify with almost all of them. 
The severity, of course, differs and, as we already said, the demographic aspect 
of SAD; someone like Norman can feel great in South Africa, not so good in 
New York, fine in Florida, but he’ll get worse if he comes here to the UK. He 
has definitely got whatever it is that causes SAD, but it varies wherever he goes 
on the planet and the same applies to me and probably millions of others. That’s 
fine if it’s mild enough that you can just adjust as with jet lag or other circadian 
rhythm disorders, but it doesn’t explain the really bad cases. 
155  Ms Jennifer Eastwood wrote: ‘I think that when SADA started and its members met other sufferers for 
the first time, we felt that we had been so traumatized by medical idiocy in the past that we wanted to take 
control of the situation and get as many sufferers properly diagnosed and treated.’ Note on draft transcript, 
31 January 2014.
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There’s just one thing that I think Norm mentioned and Chris Thompson 
published some research on, that I’d like to ask about, that is, sub-sensitivity or 
super-sensitivity to light.156 I feel, increasingly, as I get older, that what ambient 
light there is doesn’t get through to my hypothalamus. Maybe that is because for 
years I’ve been pumping hundreds of thousands of lux through my eyes so if I’m 
in somewhere semi-dark, light doesn’t really get through. Another query is why 
a lot of us fall asleep in front of our light boxes when bright light is supposed to 
keep us awake. Many of us probably have some form of sleep disorder, mainly 
Sleep Phase Delay, and realise that we were all mostly all night owls before we 
started to have SAD.157 
The difficulty is that once Professors Checkley and Thompson went and Dr 
John Eagles from Aberdeen and others retired, specialist SAD research and 
treatment seem to have disappeared in the UK. SADA was able to generate a 
lot of media interest but I sometimes wonder if it meant that the medics and 
scientific people thought: ‘Look at these awful people going on about this in the 
popular media, even The Sun’, and they didn’t approve. Maybe they switched off 
and decided that SAD wasn’t a proper illness, just a late twentieth-century fad, 
so they didn’t take it seriously. After all, you can buy a light box for a hundred 
quid, use it till you feel better, maybe tell your GP about it. Some people don’t 
even tell their GPs that they have SAD or a milder version of it.158 
Hanson: I just wanted to add a little bit to that to answer the original question. 
There were certainly bucket loads of enquiries to start with, weren’t there? And 
I think what we have now is exactly what you’d expect – a constant trickle 
of newcomers. Obviously we’ve got our core membership but we don’t get a 
huge influx like there used to be at the beginning. I think there are a lot of 
people who had been living with it for a long time and they all surfaced when 
SADA started. Now things have settled down and we are getting a steady stream 
of the next generation. The other point I wanted to make was that I think 
156  See, for example, Thompson, Stinson and Smith (1990). This paper reports evidence of super-sensitivity 
to light in the winter and sub-sensitivity in the summer.
157  Ms Jennifer Eastwood added: ‘Incidentally, while on the subject of sleep, I was once contacted by a 
Scottish lady who had had her pineal gland removed during brain surgery (the surgeon thought she didn’t 
need it!) and she could hardly sleep at all after that. I don’t know what became of her but I expect she died 
through lack of sleep.’ Note on draft transcript, 31 January 2014.
158  Ms Jennifer Eastwood wrote: ‘We need scientists like the circadian rhythm researchers to continue the 
work that began in the 1980s to take our knowledge further and enable us to understand more about this 
horrendous illness.’ Note on draft transcript, 31 January 2014.
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we’ve touched a nerve with the public and the press precisely because SAD is 
a continuum. Jennifer made the point that she was always being accosted by 
people who said that they’d got it and she said that they hadn’t. The thing is 
most human beings have it to a small extent, some people are a bit further along 
the spectrum, and then there are people like Jennifer, who are seriously affected. 
But that’s the thing that’s touched the public, I think. It’s something that they 
can all understand to a certain degree.
Follett: Winter blues.
Hanson: Yes, that’s why the press love it. I sometimes feel that the press are 
actually much more cooperative than the medical profession.
Follett: Well, that would not be a difficult step to have achieved. 
Lewy: Just to follow up on some of the things that you two have talked about: 
I don’t think the light box market is saturated. The treatment of choice is well 
known, and there still is a steady demand for buying light boxes in the USA.
Follett: What’s the market on eBay?
Lewy: Good question. I usually get several media requests to do interviews 
every winter, and it actually surprises me because you would think this would 
be old news. But I think the American public’s memory for recent news is less 
than 365 days or something [laughter], maybe 200 days. And every winter there 
Figure 15: Professor Alfred Lewy, Ms Carol Barksfield, Ms Jennifer Eastwood,  
and Ms Helen Hanson
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are reporters who say: ‘Oh boy, this would be a great story to write about’ and 
it usually occurs on some rainy, cloudy, or cold day; that’s what precipitates it. 
And I have to tell them, you know, there are many climactic and other changes 
that occur across the seasons: allergies, allergens, humidity, temperature, but 
SAD is specifically related to day length and I go into the phase shift hypothesis 
with the later sunrise being most consequential for most people. One other 
thing, because Jennifer mentioned light sensitivity tests: after we showed the 
light could suppress melatonin, in 1981 we published a small study in The 
Lancet (Tom Wehr and Fred Goodwin were co-authors) on four bipolar patients, 
who were either manic or depressed, and showed that they suppressed their 
melatonin twice the extent as did normal controls.159 This was followed up with 
John Nurnberger showing that euthymic bipolar patients, that is patients who 
were neither manic nor depressed at the time, were super-sensitive to light using 
the melatonin suppression test.160 And John Nurnberger followed that up with 
at least one other study.161 But for some reason, there hasn’t been a lot of activity 
in this area. Whether SAD patients are either super-sensitive or sub-sensitive 
to light, maybe Rob would like to comment. It’s hard to do these studies. The 
pupil accommodates to the light intensity so George Brainard was one of the 
people who dilated the pupils to make that constant, and there are other factors, 
which makes it a messy sort of test. I don’t think we really know whether SAD 
patients are super- or sub-sensitive to light. It’s a good area for future research.
Rosenthal: When I told you the other effects of light therapy, namely for 
PMS and bulimia, there’s a young Dutch researcher, Ritsaert Lieverse, who 
did a brilliant study published in the Archives of General Psychiatry on the use 
of bright light for non-seasonal depression in the elderly, and it was strongly 
positive.162 It was a wonderful, really definitive study showing that light can be 
helpful for depression in general. Dr Dixon raised a couple of points: how does 
one construct a syndrome or a condition in the absence of a definitive marker, 
which is the case for all psychiatric syndromes. The classic paper was by John 
Feighner. It was published in the 1970s. He came from the St Louis group and 
they set out a series of criteria by which you could define a condition: it had to 
be distinct from other conditions, the demographics had to fall into a certain 
159  Lewy et al. (1981).
160  Lewy et al. (1985).
161  Nurnberger et al. (2000).
162  Lieverse et al. (2011). 
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pattern, family history was a feature, clinical profile, as was course in terms of its 
natural history, response to treatment.163 And when all of these clustered around 
certain common elements then there was reason to regard the entity in question 
as a syndrome. There were different kinds of validity based on those various 
factors. Bob Spitzer does a very good paper in the book that I co-edited with 
Mary Blehar from the proceedings of the first symposium of SAD, following the 
Feighner criteria.164 For SAD there’s a common demographic profile: it is three 
times as common in women as in men; in women it starts more commonly 
after the menarche, so female sex hormones appear to be relevant. There is an 
atypical vegetative pattern of depressive symptoms in terms of oversleeping, 
overeating, carbohydrate craving, weight gain, and fatigue. These symptoms all 
appear to go together – evidence for concurrent validity. Obviously, the course 
is distinctive in terms of its seasonal variation. The response is distinctive in 
terms of the syndrome’s distinct sensitivity to light. There are all the variables 
that Feighner laid out to say that SAD is, and should be, a distinct condition. 
I should mention that there are many seasonal influences other than winter. 
Suicides peak not in the winter, but in the spring and summer. And this occurs 
both in the northern and southern hemispheres. There is a distinct form of 
163  This led to the use of the ‘Feighner criteria’ in psychiatry research which, along with the Research 
Diagnostic Criteria, were central to the development of DSM-III. See Feighner et al. (1972). 
164  Spitzer and Williams (1989).
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summer depression that has opposite vegetative symptoms to the winter 
depression (decreased sleep, loss of appetite and weight, and agitation) and it’s 
well known that suicide is more likely to occur when depression coexists with 
activation and agitation, as opposed to being slowed down and retarded. The 
latter is the case in winter depression and the former (agitation and activation) 
in summer depression. So suicides are more common in the summer. 
In terms of light sensitivity, electroretinogram studies by Marc Hébert and 
others,165 electrooculogram studies, in addition to the work that I mentioned on 
photoperiodism by Tom Wehr and myself, all suggest that people with SAD are 
sub-sensitive to light, which would explain why they need more light, in some 
cases much more light. For example, some people may need more than one 
light box at certain times. 
Now, why has the media lost interest? Well, the first thing is, it’s old news. The 
media likes new news, not old news. And so from their point of view it’s a twice-
told tale, or more what they call a soft media story. So they’ll show interest in 
the subject but the story can easily get bumped by something more important 
that comes along. The other thing that they do is they put you in cold storage. 
So I might be walking around the neighbourhood and somebody says: ‘Oh you 
were on television this morning.’ They schlep the story out of moth balls and 
put it back on the TV again without the expert even knowing. If the folks from 
SADA are wondering why you aren’t getting all the enquiries you used to get, 
think of what’s happened since the description of SAD – the internet. There was 
no significant internet back in the early 1980s. Now if you Google ‘Seasonal 
Affective Disorder’ you’ll get millions of hits. So anybody who wants help can 
go on the internet, find out the light companies, order their lights, and be done 
with it. And that’s wonderful because people should be able to get help easily. 
The last point that I would just like to mention is the question of whether 
evening light added to morning light is useful. Many patients with SAD, in my 
experience, use both evening and morning light therapy. I wonder about the 
experience of the good folks from SADA in this regard. Do you need a little 
light therapy pick-me-up in the afternoon, or you’d otherwise feel wilted?
Eastwood: The use of afternoon light is certainly encouraged, mainly because a 
lot of people don’t have time to use enough light therapy before going to work 
or school so have to top up in the evening, but as early as possible so that they 
165  See, for example, Hébert et al. (2004).
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can get to sleep at night. I’m retired now so I spend every morning glued to a 
big light box. You know that you have to just push this light through to your 
brain, it’s as simple as that. 
Lewy: As long as it’s not too late in the evening and causing a phase delay166 I’m 
fine with topping up any time in the middle of the day or late in the afternoon, 
even early evening, but not late in the evening (after 7 or 8pm) because that’s 
when you’re going to get a phase delay.167 I’d just like to add one thing about 
the seasonal pattern that Norman described. He’s absolutely correct, and it’s 
interesting that the incidents of suicide peak in the autumn, with another peak 
in the spring. But these are not – correct me if I’m wrong, Norm – regular 
seasonal cyclers who get depressed at the same season of the year, every year. 
These are cross-sectional, epidemiological of mostly non-seasonal depressives. 
These are not people who get depressed year after year after year. 
Rosenthal: No, it’s a complex issue. Some researchers have found autumn and 
spring peaks in suicide. Most people are finding the late spring and summer 
to be the peak time for suicide and this applies in both northern and southern 
hemispheres. Al is right in that the spring people, the ones who just get depressed 
in the spring, that’s not a regular pattern, but the summer people regularly get 
depressed summer after summer and it’s really sad because you can’t give them 
the relatively easy answers that are available to the winter folks. 
Lucas: I just wanted to come back to the question we were talking about 
earlier, about how it’s perceived both by the general public and by the 
scientific establishment. It may be my personal experience in the UK scientific 
establishment that the term ‘Seasonal Affective Disorder’, which I think is a 
beautiful term to have coined because it’s so descriptive of the condition, is 
regarded as kind of ‘new agey’ by some in the UK scientific establishment and 
that we suffer a little bit from that. And that may be also why the media regard 
it in a particular way. So the key feature of SAD, from a biological perspective, 
166  Lewy, Sack and Singer (1984, 1985). 
167  Professor Lewy wrote: ‘As I mentioned earlier, there is a smaller subgroup who should get bright light in 
the evening and avoid it in the morning, but in either case bright light should not be given at both times. 
A similar principle applies to treating free-running blind people with melatonin (Sack, Stevenson and Lewy 
(1990); Sack et al. (2000); Lockley et al. (2000)) so that when they entrain they do so at the normal phase 
(such that their endogenous melatonin onset occurs 2–3 hours before desired sleep onset); accordingly, most 
of them (who have endogenous periods greater than 24 hours) should take melatonin about 6pm (Lewy et 
al. (2004)), but a few of them (who have endogenous periods shorter than 24 hours) should take melatonin 
at waketime (Emens et al. (2006)).’ Note on draft transcript, 14 February 2014.
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seems to be that it’s treatable by light, so I was wondering whether if it was 
called ‘light responsive affective disorder’ that might help us out in some ways. 
And, as a counter factual thought experiment, if it was called ‘light responsive 
affective disorder’, how that would change the way that the world in general 
viewed this important condition?
Eastwood: If you call it light responsive, you’re almost putting the cart before 
the horse because, though you and I know that the original guys at NIMH 
have sorted it, you tell that to NICE or the British establishment and they 
will say: ‘Any bunch of Yanks can come up with a new condition, they’ve got 
more money for research than anybody else.’ Nobody has really proved it as 
light responsive in the UK to the satisfaction of the medical establishment. I 
completely agree that light is the fundamental element involved in SAD, but we 
can’t leave out drugs because they are the only treatment recognized by NICE, 
other than cognitive behavioural therapy of course.168 SADA has always done its 
best to present SAD to the media as respectably and positively as possible. We 
were very careful about who appeared on TV and radio on behalf of SADA; 
they had to be articulate and professional so as not to reinforce the stereotype 
of mental illness. I think that helped us to attract a lot of media attention. But 
I feel that it has only got us so far.
Lucas: Is there a country where it was called something else?
Lewy: We call it winter depression almost as often as Seasonal Affective Disorder, 
but as Norm pointed out there’s a very tiny group of people that get depressed in 
the summer on a regular basis. The original theory for the summer depressives, 
maybe Norm would like to go into that, had to do with temperature and humidity. 
But in Portland, I urge you to go there in the summer, we have little humidity, 
it doesn’t get very hot and yet we have some summer depressives. I’ve been using 
low-dose melatonin in the afternoon/evening with them to counteract the longer 
day with the chemical dark signal, melatonin, because I think that both annually 
recurrent winter and summer depression are related to circadian misalignment.169 
One occurs with the shorter days, the other occurs with the longer days. 
Rosenthal: One of the big themes in today’s whole discussion has been the 
difficulty getting this entity accepted, and as anybody who has any product, 
process, or brand name will tell you, the last thing that you want to do is change 
168  See pages 44–5 and note 109.
169  Lewy (2013).
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your name because you’ll then sow confusion among people who are already 
unaccepting and confused. So, even if we were to assume that your suggestion 
is the far better name, and Jen has contested that, you really want to be very 
careful about mixing people up, as can easily happen.
Lucas: I’m not suggesting it.
Arendt: I think SAD is a wonderful name but I think Rob is right, that it is 
seen as slightly alternative. A couple of days ago, I went to something called 
the Shuffle Festival, which is in a disused psychiatric hospital in the Mile End 
Road. It’s run by Danny Boyle’s daughter, Grace Boyle, and it featured winter 
depression and a light treatment room among all sorts of other things.170 
Follett: Let me draw it together. First of all I’d like to thank everybody for 
coming and particularly our colleagues who have come over the Atlantic to these 
northern latitudes on December 10th, so close to the winter solstice. Also, of 
course, Queen Mary and the Wellcome Trust who’ve put all this on. I leave it 
170  The first Shuffle Festival, an initiative of the East London Community Land Trust, exploring artistic 
talent in London’s East End, was held in August 2013 at St Clement’s Hospital, a former workhouse and 
psychiatric hospital in Mile End. A Winter Shuffle was held in December 2013. See the Shuffle website at 
www.shufflefestival.com (visited 3 June 2014), and the filmed recording of the lecture given by Professor 
Jo Arendt, ‘Light, Dark and living in Antarctica’, at www.youtube.com/watch?v=vMGgbtkoYN4 (visited 
3 June 2014). Danny Boyle (b. 1956) is a film director, producer, and writer.
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with one observation – it’s really Rob’s point: there is a treatment and it appears 
to work. It’s not actually a difficult treatment, it may not be entirely pleasant but 
nevertheless it is straightforward and it is not regulated by the NHS. So isn’t the 
answer ‘get the message out’. It would be good if NICE agreed that half the price 
or so of a light box was paid by the taxpayer, but the cost of around £150 is not 
that great. So I’m optimistic on the treatment front but much less so on our ability 
to understand the underlying physiology. Frankly it is going to be impossible to 
solicit millions of dollars to unravel this problem. We do not have a good animal 
model to understand how daylight-length affects ‘mood’. And therefore I come 
away from it feeling, why haven’t we got billboards advertising it? 
Tansey: May I add my thanks and the thanks of my team to you all for coming 
and being so frank, opening up so many questions and issues. I’m very conscious 
we haven’t even addressed some of them. I do apologize about the timing: we did 
realise that a December afternoon was not ideal for this meeting but we want 
to try and get something out for next year because it is the 30th anniversary of 
the very first SAD paper and Thomas Dixon and I have an idea that we’d like to 
have a press campaign for ‘SAD at 30’ or something like that. And, finally, I do 
want to thank our excellent chairman. Thank you so much, Brian.
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Appendix 1
Regulations with which light boxes need to comply171
Medical Directive 93/42/EC amended 2007/47/EC – Main Directive 
from Europe, which covers the regulation of Medical Devices.  Light boxes 
are considered to be an invasive device under Annex IX, as they change the 
chemical balance in the brain 
BS EN 60601-1:2006 – Medical electrical equipment Part 1: General 
requirements for safety
BS EN 60601-1-2:2007 – Medical electrical equipment Part 1–2:  General 
requirements for safety – Collateral standard: Electromagnetic compatibility – 
Requirements and tests
BS EN 60601-2-57 – Medical electrical equipment.  Particular requirements for 
the basic safety and essential performance of non-laser light source equipment 
intended for therapeutic, diagnostic monitoring, cosmetic/aesthetic use 
BS EN 1031: 2008 – Information supplied by the manufacturer with medical 
devices.  This covers what is to be put in the Instructions for Use 
BS EN 980: 2008 – Graphical symbols for use in labelling of medical devices
BS EN ISO 14971:2009 Medical devices – Application of risk management 
to medical devices. Revised 2012
BS EN ISO 13485:2003 – Medical Devices Quality Management System. 
Revised 2012 
171  Information supplied by Ms Carol Barksfield, who wrote: ‘We have the light boxes tested to all the 
above standards and it is mandatory to comply with the overarching Medical Directive from Brussels, 
93/42/EC.  We were one of the first medical device companies and the first light box manufacturer to 
attain the Quality System, BS EN ISO 13485. This is not mandatory but we hold this as I thought that 
if we were manufacturing light boxes it was silly not to.’ Email to Ms Caroline Overy, 8 April 2014. 
BS EN ISO  3485 is a key standard to measure the quality of medical equipment, medical instruments, and 
medical technology.
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Appendix 2
The Seasonal Pattern Assessment Questionnaire172
172  This questionnaire is in the public domain and downloaded from www.guilford.com/
add/forms/rosenthal2.pdf?viewpdf (visited 10 June 2014).
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Appendix 3
Daily Mood Log173
173  The Daily Mood Log is reproduced from Rosenthal N E. (2013) Winter Blues, 4th 
edn. New York: The Guilford Press, page 328. Copyright: Guilford Press. Reprinted with 
permission of The Guilford Press.
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Professor Josephine Arendt 
PhD, FRCPath, FRSM, 
Dr med h c (b. 1941) is Emeritus 
Professor of Endocrinology at the 
University of Surrey, Emeritus 
Director of the Centre for 
Chronobiology, and Director of 
Stockgrand Ltd, a company that 
she founded in 1988 to exploit 
expertise in light and melatonin. 
She is a founding member of the 
European Biological Rhythms 
Society (previously the European 
Pineal Society) and of the Society 
for Light Treatment and Biological 
Rhythms. She was President of 
The European Pineal Society 
(1987–1990), President of the 
Gordon Research Conference on 
Pineal Cell Biology (1998–2000) 
and has been awarded a number 
of medals (St Goran’s Hospital, 
Karolinska Institute, Justus von 
Liebig University, Giessen, the 
Ernst and Berta Scharrer Medal, 
University of Frankfurt and the 
Kappers Medal of the European 
Biological Rhythms Society). She 
has served on a number of editorial 
boards, including Associate 
Editorship and currently has 
editorial board membership of the 
Journal of Biological Rhythms. She 
was an expert adviser to the IARC 
(WHO) group on the cancer risks 
of shift work, together with other 
committees related to melatonin, 
light, and chronobiology. She 
pioneered immunotechnology for 
the detection and measurement of 
melatonin and its metabolites, their 
circadian and seasonal response to 
light, and their use to characterize 
circadian responses, particularly 
in conditions such as jet lag and 
shift work. She first described 
the chronobiotic properties of 
melatonin in relation to sleep and 
the circadian system, and initiated 
its use for circadian rhythm-related 
sleep disorders, such as jet lag and 
non-24h sleep disorder of the blind. 
She highlighted the importance 
of light and melatonin in humans 
and continues to pursue research 
interests in this area, particularly in 
polar regions.
Ms Carol Barksfield
BA (b. 1954) studied Business 
Administration at Brunel 
University. She took over as 
Managing Director of SAD 
Lightbox Company in July 1996 
and in 1998 successfully steered 
the company through the Medical 
Directive 93/42 to become the first 
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light box company in the UK to 
achieve this certification. She has 
since guided it through the Medical 
Quality Standard ISO1348, again 
the first UK light box company 
to gain this qualification. Since 
taking over the company, the 
range of light boxes manufactured 
has evolved to embrace the latest 
designs and technology. The 
light boxes have been used in the 
Dana Centre, part of the Science 
Museum to promote public 
awareness of Seasonal Affective 
Disorder. All the light boxes are 
widely used in clinical trials, most 
recently by Outlook Southwest, 
UCL, and in clinical trials in 
Amsterdam and Madrid. 
Professor Stuart Checkley 
FRCPsych, FRCP, FKC (b. 1945) 
qualified in medicine at the 
University of Oxford in 1970, 
and after house appointments 
was a Registrar in Psychiatry at 
the London Hospital (1974–
1976). In 1976 he moved to the 
Maudsley Hospital, London, 
where he where was Consultant 
Psychiatrist from 1981 to 2001. 
He was Dean at the Institute 
of Psychiatry, King’s College 
London, from 1989 to 2001. He 
is currently a retired consultant 
psychiatrist at the Maudsley 
Hospital, and Emeritus Professor of 
Psychoneuroendocrinology. 
Professor Philip Cowen
MD FRCPsych (b. 1951) trained 
in medicine at University College 
Hospital, London, and then 
in psychiatry at King’s College 
Hospital, London. He went to 
Oxford to work in the MRC Unit 
of Clinical Pharmacology. Since 
1983 he has been an MRC Clinical 
Scientist and Honorary Consultant 
Psychiatrist in the Department 
of Psychiatry in Oxford. He 
was elected to a personal chair 
in Psychopharmacology in the 
University of Oxford in 1997 and 
the Academy of Medical Sciences 
in 2001. His main interests are in 
the biochemistry and treatment of 
mood disorders, particularly the 
pharmacological management of 
resistant depression.
Professor Ilana Crome 
MD FRCPsych (b. 1951) is 
Emeritus Professor of Addiction 
Psychiatry, Keele University and 
Honorary Consultant Psychiatrist, 
South Staffordshire and Shropshire 
Healthcare NHS Trust. She is Past 
President of the Alcohol and Drugs 
Section of the European Psychiatric 
Association, international editor 
of American Journal of Addictions, 
and on the International Advisory 
Boards of the British Journal of 
Psychiatry, Addiction, and Journal of 
Psychopharmacology. She was Chair 
of the Faculty of Substance Misuse 
(1998–2002), currently a co-opted 
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member of the Addictions Faculty, 
and founding member of the 
Academic Faculty (2005–2012) at 
the Royal College of Psychiatrists. 
She was a member of the Advisory 
Council on the Misuse of Drugs 
(ACMD) (2002–2010), and was 
Chair of the Treatment Working 
Group; she sat on the Executive 
of the Society for the Study of 
Addiction (1994–2011). She is 
a Trustee on the Independent 
Scientific Committee on Drugs 
and Vice-Chair of the Professors of 
Psychiatry Club. Her continuing 
research interests include addiction 
along the life course, and the 
enhancement of training and 
education in substance misuse in 
health professionals at all levels. 
Dr Thomas Dixon
PhD (b. 1973) completed his 
PhD and held a British Academy 
Postdoctoral Fellowship at 
the University of Cambridge 
(2000–2003). He was a Lecturer 
in History at Lancaster University 
from 2004 until 2007, when he 
joined the School of History at 
QMUL. Since 2008 he has been 
Director of the Queen Mary Centre 
for the History of the Emotions. 
His current research interests are in 
the histories of emotions (especially 
tears and weeping), medicine and 
science, and in the cultural history 
of philosophy (including stoicism 
and existentialism). Previous 
research projects have explored the 
histories of psychological categories, 
Victorian moral thought, and the 
relationships between science and 
religion.
Ms Jennifer Eastwood
BA PGCE (b. 1952) graduated 
in French from the University of 
Newcastle in 1973 and moved with 
her husband to London to start her 
career, initially teaching, then in 
the Civil Service. Her aim was to 
become an arts administrator and 
in 1977 she was awarded funding 
by the Arts Council of Great 
Britain to set up the Early Music 
Network, a nationwide series of 
100 concerts of music from the 
thirteenth to eighteenth centuries. 
She continued to run the series, 
along with other freelance activities 
in early music, music education, 
broadcasting, and writing, until 
1983, when her health prevented 
her from continuing with creative 
and executive work. She undertook 
various part-time administrative 
jobs while struggling with her 
mental health and undergoing 
many operations for an unrelated 
physical condition. She started 
employment with Imperial College 
London in 1985 when her health 
problems were under control and 
spent the remainder of her working 
life there as support staff for several 
different research groups. In 1987 
she set up the SAD Association to 
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raise awareness of SAD and ensure 
that sufferers were able to access 
treatment. Her interests include 
singing and getting away from the 
UK as often as possible.
Professor Sir Brian Follett
FRS PhD DSc (b. 1939) graduated 
in biological chemistry followed by 
a PhD in pharmacology. He held a 
series of academic posts in zoology/
biology departments over the 
next 30 years in Washington State 
University, University of Leeds, 
University of Wales Bangor, and 
University of Bristol.  His research 
focused upon seasonal breeding 
in birds and mammals and he was 
Director of the BBSRC Research 
Group on Photoperiodism and 
Reproduction.   In all, about 
420 papers emanated from the 
Group, with especial emphasis 
upon endocrinology, the neural 
pathways involved in controlling 
reproduction, and the biological 
clocks used to measure day length.  
This research was carried out on 
a range of birds (quail, starlings, 
albatrosses, ducks) and mammals 
(hamsters, sheep).  He was elected 
to the Royal Society in 1984 and 
was later its Biological Secretary.  
In parallel, he had a growing 
administrative focus and was Head 
of Zoology in Bristol for 14 years 
before being appointed to the Vice-
Chancellorship of the University 
of Warwick in 1992. Nationally 
he served on the council of AFRC, 
the UFC, and HEFCE. He has 
chaired government enquiries and 
reported on university libraries, 
JISC (for HEFCE), Creation 
of an Arts Research Council 
for the British Academy/ESRC, 
the Foot-and-Mouth Disease 
Outbreak of 2001, and the Alder 
Hey Children’s Hospital scandal 
of 2001. After ending his stint at 
Warwick University he became 
Non-executive Chair of the Teacher 
Training Agency (2003–2009) and 
the Arts and Humanities Research 
Council (2001–2008).  Since 2002 
he has been a (visiting) Professor 
of Zoology at Oxford, where he 
lectures undergraduates. He has 
received various honours from UK 
and foreign universities. 
Professor Frederick Goodwin
MD (b. 1936) received his MD 
from St Louis University School 
of Medicine in 1963 and joined 
the NIMH in 1965 where he was 
Scientific Director (1981–1988) 
and Director (1992–1994). 
Between 1988 and 1992 he 
was head of the Alcohol, Drug 
Abuse, and Mental Health 
Administration. In 1994, he was 
appointed Research Professor of 
Psychiatry and Director of the 
Center on Neuroscience, Medical 
Progress, and Society at the George 
Washington University Medical 
Center, becoming Clinical Professor 
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of Psychiatry in 2008. His research 
focuses on psychopharmacology, 
especially bipolar disorder, major 
depression, and suicide. He is the 
author of over 460 publications, 
including the textbook, Manic-
Depressive Illness: Bipolar Disorders 
and Recurrent Depression (with 
Kay Redfield Jamison), and from 
1998 to 2005 he hosted the weekly 
public radio show, The Infinite 
Mind (guest host until 2007). 
Ms Helen Hanson
BA (b. 1950) read French and 
Italian at Bedford College, 
University of London. She went 
into teaching, becoming Head of 
Modern Languages and Director 
of Personal and Social Education 
in a Kent comprehensive school. 
In 1990, following the success 
of her work as a printmaker, 
she left education to become a 
professional artist. She exhibited 
her etchings throughout the UK 
and abroad, was a member of 
Greenwich Printmakers, and a 
founder member of South Bank 
Printmakers. She has also been a 
member of the Society of Botanical 
Artists for many years and organizes 
Florum, a major annual exhibition. 
She was diagnosed with SAD in 
1991 and helped as a volunteer in 
the early years of SADA, returning 
to join the committee in 2012. 
She has been Chairman since 
May 2013.
Professor Alfred Lewy
BS MD PhD (b. 1945) graduated 
in biochemistry from the 
University of Chicago in 1967 
and obtained his MD and PhD in 
pharmacology in 1973. His PhD 
dissertation on operant behaviour 
and norepinephrine metabolism 
was published in Science in 1972. 
He was a house officer at Mt Zion 
Hospital between 1973 and 1975, 
finishing his residency in psychiatry 
at the National Institute of Mental 
Health (NIMH) in Bethesda 
MD. He was a Clinical Associate 
and then a Staff Psychiatrist 
at the NIMH until 1980, and 
then he was a Guest Worker at 
the National Eye Institute until 
his move to Oregon Health & 
Science University in 1981, where 
he became Director of the Sleep 
and Mood Disorders Laboratory, 
eventually becoming Professor 
of Psychiatry, Ophthalmology 
and Physiology/Pharmacology. 
In the Department of Psychiatry, 
he was appointed Vice-Chair in 
1998 and then Senior Vice-Chair 
in 2003. In 2004, he became the 
Richard H. Phillips Professor of 
Biological Psychiatry. Upon his 
retirement in 2014, he became 
Professor Emeritus, Department of 
Psychiatry. He has published more 
than 240 scientific papers and book 
chapters, and he has given more 
than 410 scientific and professional 
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lectures, courses, and presentations. 
He has received several honours for 
his contributions, including a 2011 
University of Chicago Alumni 
Professional Achievement Award 
for his work on the use of light 
and melatonin in the elucidation 
and treatment of circadian rhythm 
disorders, such as occur in Seasonal 
Affective Disorder and in totally 
blind people.
Professor Gerald Lincoln 
PhD ScD FRSE (b. 1945) was 
brought up on a farm in Norfolk 
and followed his elder brothers 
Dennis and Roger into academic 
careers. His first success was the 
award in 1964 of the Prince 
Philip Prize for zoology from the 
Zoological Society of London. 
After reading Zoology at Imperial 
College London, he gained a PhD 
degree from the University of 
Cambridge in 1972, mentored by 
Professor Roger Short. The thesis 
was based on work on red deer 
on the Isle of Rum. This kindled 
a career in chronobiology. The 
research was then funded by the 
Medical Research Council at the 
MRC Centre for Reproductive 
Biology in Edinburgh (later 
Human Reproductive Sciences 
Unit). The aim was to unravel 
the mechanistic basis of seasonal 
breeding – Nature’s Contraceptive. 
He received medals from the UK 
Endocrine and Neuroendocrine 
Societies and was elected a Fellow 
of the Royal Society of Edinburgh 
in 1993. He joined the University 
of Edinburgh in 2005, and is 
now retired as ‘Emeritus Professor 
of Biological Timing’, working 
in nature conservation (www.
puddledub.org/). His publications 
include Lincoln (2001/2, 2014) 
and Lincoln et al. (2006). 
Professor Rob Lucas
PhD (b. 1968) graduated from 
the University of York with a BSc 
in biological sciences in 1989. 
He subsequently worked in the 
pharmaceutical industry for three 
years before returning to graduate 
study in the laboratory of Andrew 
Loudon at the Institute of Zoology, 
University of London. In 1996 he 
completed his PhD thesis in the 
field of reproductive endocrinology. 
He then undertook post-doctoral 
research on circadian photobiology 
under the mentorship of Russell 
Foster at Imperial College London, 
and obtained his first independent 
academic position in 2000 when 
he was awarded a Governors 
Lectureship in the Faculty of 
Medicine at Imperial College. He 
moved to a Senior Lectureship at 
the University of Manchester in 
2003, where he was appointed 
Professor of Neurobiology in 2006. 
He currently holds the GSK chair 
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in Neuroscience in the Faculty 
of Life Sciences, University of 
Manchester.
Professor Norman Rosenthal 
MD (b. 1950) was born in 
Johannesburg, South Africa. He 
graduated as a medical doctor with 
high honours from the University 
of Witwatersrand in 1973. He 
immigrated to the United States, 
where he did his psychiatry 
residency and became Chief 
Resident. In 1979, he joined the 
National Institute of Mental Health 
in Bethesda, Maryland, where he 
became first a research fellow and 
later a tenured researcher. It was 
there in 1984 that he led the team 
that first named and described 
Seasonal Affective Disorder (SAD), 
and pioneered the use of light 
therapy for its treatment. The paper 
subsequently became a citation 
classic and has been cited well over 
100 times. He has authored or co-
authored hundreds of subsequent 
papers on SAD, light therapy, and 
related topics. Along with colleague 
Thomas Wehr, in 1991 he was 
awarded the Anna-Monika Prize for 
depression research for his work in 
this area. He is also a best-selling 
author, whose book Winter Blues, 
now in its fourth edition, has been 
described as ‘a classic work’ by 
the New York Times. He has also 
written seven other books for the 
general public. He is currently 
Clinical Professor of Psychiatry 
at Georgetown University. He 
maintains a private practice in 
Bethesda, Maryland and continues 
to research innovative treatments 
for depression and other psychiatric 
disorders.
Professor Tilli Tansey
OBE PhD PhD DSc HonFRCP 
FMedSci (b. 1953) graduated in 
zoology from the University of 
Sheffield in 1974, and obtained her 
PhD in Octopus neurochemistry 
in 1978. She worked as a 
neuroscientist in the Stazione 
Zoologica Naples, the Marine 
Laboratory in Plymouth, the MRC 
Brain Metabolism Unit, Edinburgh, 
and was a Multiple Sclerosis Society 
Research Fellow at St Thomas’ 
Hospital, London (1983–1986). 
After a short sabbatical break at 
the Wellcome Institute for the 
History of Medicine (WIHM), 
she took a second PhD in medical 
history on the career of Sir Henry 
Dale, and became a member of the 
academic staff of the WIHM, later 
the Wellcome Trust Centre for the 
History of Medicine at UCL. She 
became Professor of the History 
of Modern Medical Sciences 
at UCL in 2007 and moved to 
Queen Mary, University of London 
(QMUL), with the same title, in 
2010. With the late Sir Christopher 
Booth she created the History 
of Twentieth Century Medicine 
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Group in the early 1990s, now the 
History of Modern Biomedicine 
Research Group at QMUL.
Professor Chris Thompson
MD FRCP FRCPsych MRCGP 
FRSA (b. 1952) qualified in 
medicine at UCL in 1977. After 
posts at the Maudsley Hospital 
and the Institute of Psychiatry, he 
was appointed Senior Lecturer in 
Psychiatry at the Charing Cross 
Hospital Medical School (1984–
1988), before becoming Professor 
of Psychiatry at the University of 
Southampton in 1988 and Head 
of the Medical School from 2001. 
He was appointed Chief Medical 
Officer of Priory Group in 2004 
and Director of Public Affairs in 
2012. He was one of the early SAD 
researchers, having SAD clinics, 
first at Charing Cross Hospital 
and then at the University of 
Southampton.
Dr Thomas Wehr 
MD (b. 1941) received his MD 
from the University of Louisville 
School of Medicine in 1969. After 
a residency in psychiatry at Yale 
University School of Medicine 
he was based at the National 
Institute of Mental Health in 
Bethesda (NIMH) from 1973 
until his retirement in 2003, 
where he was Chief of the Clinical 
Psychobiology Branch from 1982 
to 1999 and then Chief of the 
Section on Biological Rhythms. He 
is currently Scientist Emeritus and 
in private psychiatry practice in 
Bethesda, MD. His research at the 
NIMH focused on the prevention 
and treatment of mood disorders, 
and his group was the first to 
describe SAD and demonstrate that 
the depression responds to light 
treatment. He was awarded the 
Anna-Monika Prize in 1981 (with 
Anna Wirz-Justice) and 1991 (with 
Norman Rosenthal) for research on 
depression.
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